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V Summary 
Protein arginine methylation represents a posttranslational modification undertaken 
by protein arginine methyltransferases (PRMT) that results in production of protein-
incorporated ω-NG-monomethylarginine (L-NMMA), asymmetric ω-NG, NG-
dimethylarginine (ADMA), or ω-NG, N' G-dimethylarginine (SDMA). Free cellular L-
NMMA, ADMA and SDMA can be generated via the proteolytic cleavage of intracellular 
proteins, thereby also affecting methylarginine content in the plasma. Free 
methylarginines can be cleared from the body by renal excretion. L-NMMA and ADMA, 
but not SDMA, can be degraded via enzymes called NG, NG–dimmethylarginine 
dimethylaminohydrolase (DDAH). 
ADMA is an endogenous inhibitor of nitric oxide synthases (NOS) and a marker of 
endothelial dysfunction. Increased plasma ADMA levels have been reported in patients 
with cardiovascular disorders including pulmonary arterial hypertension (PAH), a fatal 
disease characterized by elevated blood pressure in the pulmonary circulation, due to 
increased resistance of pulmonary arterioles. The major pathophysiologic hallmark of 
PAH is pulmonary arterial smooth muscle cell (PASMC) hypertrophy and proliferation, 
leading to the occlusion of pulmonary arterioles. The interplay between methylarginine 
synthesis and degradation in vivo, as well as specific alterations to intrapulmonary 
ADMA levels or distorted generation of ADMA in PAH, however, remains to be 
elucidated. 
In the current study, we hypothesized that methylarginine production and degradation 
is tissue-specific and that the lung has a significant impact on serum/plasma ADMA 
levels, possibly leading to endothelial dysfunction observed in PAH. To this end, we 
sought to address the following specific aims: 1) to develop a novel, HPLC-based method 
to assess protein-incorporated and free cellular methylarginine content in biological 
samples, 2) to analyze the tissue-specific methylarginine metabolism in normal subjects, 
and 3) to analyze the methylarginine content in the lungs of patients with PAH compared 
with healthy donors. 
Summary  XV 
First, to analyze tissue-specific methylarginine metabolism in the normal 
physiological state, we performed high performance liquid chromatography  
(HPLC)-driven assessment of protein-incorporated and free cellular methylarginine 
levels, together with Western blot analyses of PRMT and DDAH expression, in organs of 
the cardiovascular system. Our results revealed that pulmonary expression of type I 
PRMT was correlated with enhanced protein arginine methylation in the lung. Moreover, 
our studies also revealed that the kidney and the liver provide complementary routes for 
clearance and metabolic conversion of circulating ADMA.  
To address the impact of intrapulmonary ADMA metabolism in pathogenic 
conditions, we next analyzed lung homogenates of PAH patients. HPLC analysis revealed 
significantly lower levels of protein-incorporated ADMA in the lungs of PAH patients 
(n=12), compared with controls (n=10, transplant donors). Western Blot analyses 
confirmed a significantly decreased content of asymmetrically dimethylated proteins in 
PAH lungs. The expression of PRMT, in particular PRMT1, was decreased in PAH. 
Immunohistochemical staining of IPAH and control lungs localized PRMT1 to 
pulmonary arterial vascular smooth muscle cells (PASMC). Moreover, PRMT1 
knockdown in primary PASMC by siRNA technology significantly increased PASMC 
proliferation.  
Our results demonstrate that, in the normal physiological state, methylarginine 
metabolism by the pulmonary system significantly contributes to circulating 
methylarginine levels. In pathogenic conditions, protein-incorporated ADMA 
concentrations do not reflect free cellular levels of ADMA in the lung. This may be 
explained by the alterations of DDAH activity in the lung, which, consequently, regulate 
ADMA content in the serum of IPAH patients. In addition, our studies demonstrated a 
novel regulatory role of PRMT1 in progression of PAH, by the alteration of PASMC 
proliferation, a major characteristic of PAH. This led to conclusions that protein arginine 
methylation plays a pivotal role in the pathogenesis of PAH. 
 
 
Zusammenfassung  XVI 
VI Zusammenfassung 
Posttranslationale Protein-Arginin Methylierung erfolgt durch eine Gruppe 
spezifischer Protein-Arginin Methyltransferasen (PRMTs), die neben der Bildung von 
asymmetrischem Dimethylarginin (ADMA) auch für die Synthese von 
Monomethylarginin (L-NMMA) und symmetrischem Dimethylarginin (SDMA) 
verantwortlich sind. Die Freisetzung von Methylarginine in das Blutplasma erfolgt nach 
heutigem Wissensstand über die Proteolyse zellulärer, methylierter Proteine. Alle 
Methylargininformen werden über renale Exkretion aus dem Körper eliminiert. Neuere 
Studien heben die Metabolisierung von ADMA und L-NMMA durch das Enzym 
Dimethylarginin-Dimethylaminohydrolase (DDAH) als Hauptabbauweg hervor. 
ADMA ist ein endogener Inhibitor der NO-Synthase und ein Marker für endotheliale 
Fehlfunktion. Eine erhöhte ADMA Konzentration im Blut wird bei verschiedenen 
kardiovaskulären Erkrankungen, so auch bei pulmonal-arterieller Hypertonie (PAH), für 
einen Mangel an biologisch verfügbarem NO verantwortlich gemacht. Die pulmonal-
arterielle Hypertonie ist durch eine pathologische Hypertrophie und Proliferation 
pulmonalarterieller glatter Muskelzellen (PASMC) gekennzeichnet, die eine Okklusion 
pulmonaler Arteriolen zur Folge hat. Ob ein Zusammenhang zwischen Arginin- und 
Dimethylargininstoffwechsel und den bei PAH zu beobachtenden Symptomen vorliegt, 
wurde bislang nicht untersucht.  
Deshalb sollte in der vorliegenden Studie geprüft werden, ob der Methylarginin-
metabolismus der Lunge signifikant zur ADMA Konzentration im Blut beiträgt und 
somit an der Ausbildung endothelialer Fehlfunktionen beteiligt sein könnte. Im 
Konkreten sollten hierfür folgende Vorhaben realisiert werden: (1) Entwicklung einer auf 
Hochdruckflüssigkeitschromatographie-basierenden Methode zur Quantifizierung von 
protein-inkorporiertem und freiem Methylarginin in biologischen Proben, (2) Analyse des   
gewebespezifischen Methylargininmetabolismus und (3) Bestimmung des pulmonalen 
Methylarginingehaltes von PAH Patienten und gesunden Organspendern. 
Zur Beschreibung des Methylargininmetabolismus unter normalen physiologischen 
Bedingungen wurden protein-inkorporiertes und freies Methylarginin in Organen des 
Zusammenfassung  XVII 
kardiovaskulären Systems bestimmt. Zudem wurde vergleichend Proteinexpression und 
Aktivität der PRMTs und DDAHs ermittelt. Unsere Untersuchungen ergaben eine klare 
Korrelation zwischen pulmonaler Typ I PRMT Proteinexpression und erhöhter Protein-
Arginin Methylierung. Zudem konnte gezeigt werden, dass Niere und Leber 
komplementär an der Eliminierung und Metabolisierung von ADMA und L-NMMA 
beteiligt sind. 
Zur Beurteilung der Frage, ob bei PAH ein geänderter Dimethylargininstoffwechsel 
zu beobachten ist, wurde Lungenhomogenat mittels HPLC untersucht. Die Analyse bei 
PAH Patienten (n=12) und gesunden Organspendern (n=10) ergab eine signifikante 
Abnahme an protein-inkorporiertem ADMA bei PAH Patienten. Zudem konnte über 
Western-Blot Analyse ein reduzierter Gehalt an asymmetrisch dimethylierten Proteinen 
nachgewiesen werden. Bei PAH Patienten zeigte sich auch eine signifikant reduzierte 
Expression jener Protein-Arginin-Methyltransferasen, insbesondere PRMT 1, die für eine 
asymmetrische Dimethylierung von Zielproteinen verantwortlich sind. 
Immunohistochemische Untersuchungen führten zu dem Ergebnis, dass PRMT 1 
überwiegend in PASMCs lokalisiert ist. Zudem resultierte die Reduktion der PRMT 1 
Expression mittels siRNA Technologie in einer Zunahme der PASMC Proliferation.  
Aus den vorliegenden Ergebnissen lässt sich somit schlussfolgern, dass der 
pulmonale Dimethylargininmetabolismus maßgeblich zum Plasma ADMA-Spiegel 
beiträgt. Bei PAH Patienten konnte keine Korrelation zwischen protein-inkorporiertem 
ADMA und freiem Methylarginin nachgewiesen werden. Dieses Ergebnis deutet auf eine 
Änderung der pulmonalen DDAH Aktivität und Plasma ADMA-Werte bei PAH 
Patienten hin. Des Weiteren konnte eindeutig demonstriert werden, dass PRMT 1 an der 
Regulation der PASMC Proliferation beteiligt ist. Zusammenfassend lässt sich somit 
feststellen, dass Protein-Arginin Methylierung an der Entwicklung und am Fortschreiten 
von PAH beteiligt sein könnte. 
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1 Introduction 
1.1 ADMA metabolism 
1.1.1 ADMA synthesis 
Asymmetric dimethylarginine (ADMA) is an amino acid derivative, circulates in 
the plasma, is excreted in the urine, and found in broncho-alveolar lavage fluid (BALF). 
During the last 30 years, the occurrence of ADMA has been extensively studied in the 
cell and in tissues (McDermott 1976; Vallance et al. 1992; Cooke 2000). The ADMA is 
synthesized during methylation of protein L-arginine residues by the action of specific 
enzymes called protein arginine methyltransferases (PRMT) (Clarke 1993; McBride and 
Silver 2001; Boisvert et al. 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Methylarginines are generated during methylation of 
protein L-arginine residues. Type I PRMTs catalyze the formation 
of L-NMMA and ADMA, while type II PRMTs are responsible for 
generation of L-NMMA and SDMA. S-adenosylmethionine (SAM) 
is a substrate for this reaction and converts to  
S-adenosylhomocysteine (SAH) (Blanchet et al. 2006). 
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This posttranslational protein modification results in the addition of one or two 
methyl groups to the guanidino nitrogen atoms of  L-arginine (Gary and Clarke 1998). 
Three main forms of methylated L-arginine have been identified in eukaryotes:  
ω-NG-monomethylarginines (L-NMMA), asymmetric ω-NG, NG-dimethylarginine 
(ADMA), and ω-NG, N' G-dimmethylarginine (SDMA) (figure 1.1) (Vallance et al. 1992). 
Free cellular methylargines are released through proteolysis of mono- and  
di-methylated proteins in the cytosol. Previous studies demonstrated that production and 
elimination of methylated proteins in the cell is closely correlated to total proteome 
synthesis and degradation (Miyake and Kakimoto 1976). To date, there is no evidence for 
the generation of L-NMMA, ADMA and SDMA from free L-arginine through an 
enzyme-catalyzed reaction. In addition, demethylation of free methylarginines has not 
been demonstrated yet. Thus, protein turnover and type I PRMT activity in the cell 
together might control intracellular ADMA levels (Vallance et al. 1992). 
 
1.1.1.1 The PRMT family of enzymes: biological function 
Eleven PRMTs have been identified in humans. The PRMTs have been classified 
into two groups: type I and type II, depending on enzyme activity. All PRMTs can 
catalyze the formation of L-NMMA, while type I PRMTs form ADMA and type II, 
SDMA (Bedford and Richard 2005). The members PRMT1, PRMT3, PRMT4, PRMT6 
and PRMT8 belong to the type I group, while PRMT5, PRMT7 and PRMT9 belong to 
the type II group (figure 1.2). Although PRMT2 is structurally very similar to PRMT1, 
enzymatic activity has not been demonstrated to date (Scott et al. 1998). Furthermore, 
PRMT10 and PRMT11 enzymatic activity has not been demonstrated. 
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All PRMTs contain an S-adenosyl methionine (SAM) binding domain, with conserved 
motifs I, II, and III and a substrate binding domain. Additionally, PRMT2 and PRMT3 
possess a SH3 and Zn2+ finger domain, respectively, which increase the specificity for 
substrate binding (Bedford and Richard 2005) (figure 1.2). 
Proteins which have been demonstrated as PRMT substrates harbor glycine and 
arginine-rich (GAR) conserved motifs, often RGG, RXR and RG, where R indicates  
L-arginine, G, glycine and X, any amino acid (Najbauer et al. 1993). The PRMT targets 
have been identified by different approaches: during the identification of new interaction 
partners (Abramovich et al. 1997; Chen et al. 1999; Passos et al. 2006; Nicod 2007), 
through in vitro substrate screens (Lee and Bedford 2002; Wada et al. 2002; Kim et al. 
2004) or by proteomic-based mass spectrometric approaches (Boisvert et al. 2003; Ong et 
al. 2004). 
Methyltransferases regulate several cellular processes in bacteria, yeast and 
mammalian cells. These enzymes are implicated in the modulation of nuclear export 
(McBride et al. 2005) and import (Xu et al. 2001), or protein-protein interaction (Bedford 
Figure 1.2 The protein arginine methyltransferase family. 
Currently, 11 PRMTs have been identified. The mammalian 
methyltransferases contain conserved motifs: post I, II, III (black), 
SAM (dark grey) and substrate (light grey) binding domain. 
PRMT2 and PRMT3 have SH3 and zinc finger domain, 
respectively. Both PRMT7 and PRMT10 harbor a repetition of 
PRMT conserved motifs. The length of the proteins is indicated by 
the number of amino acids (modified from Pahlich et al. 2006). 
SAM 
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II I III 
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et al. 2000). They are also involved in RNA processing (Cote et al. 2003), signal 
transduction (Mowen et al. 2004), transcription (Hassa et al. 2008) and DNA repair 
(Boisvert et al. 2003; Boisvert et al. 2005) (tabele1.1). 
 
 
 
 
PRMT Type Biological functions 
PRMT1 I Transcriptional activation (H4R3), nuclear 
localization, DNA repair, signaling 
PRMT2 ? Transcriptional coactivator, nuclear retention, 
apoptosis 
PRMT3 I Ribosome assembly 
PRMT4/CARM1 I Transcriptional activation (H3R2, H3R17, 
H3R26), muscle differentiation, T cell 
development, tumorigenesis 
PRMT5 II Transcriptional repression (H3R8 and H4R3), 
PRMT6 I HIV replication, DNA repair 
PRMT7 II Imprinting in male germ cell (H4R3) 
PRMT8 I Unknown 
PRMT9 II Unknown 
PRMT10 ? Unknown 
PRMT11 ? Unknown 
 
 
 
The predominant methyltransferase in mammalian cells is PRMT1 and 85% of 
cellular protein arginine methylation appears to be performed by this enzyme (Gary and 
Clarke 1998; Pawlak et al. 2002). The PRMT1 was first identified as an interaction 
partner of the BTG/TOB protein family (BTG1, BTG2) (Lin et al. 1996) and the 
cytoplasmic domain IFNAR1 chain of the α, β interferon receptor, using a yeast two 
hybrid screen (Abramovich et al. 1997). The PRMT1 is localized to the nucleus (Frankel 
et al. 2002; Passos et al. 2006; Robin-Lespinasse et al. 2007), while cytosolic localization 
of this enzyme was also observed under native and modified conditions in various cell 
Tabele 1.1 List of Protein arginine methyltransferases and their biological functions. H 
indicates histone and R methylated arginine residue implicated in protein methylation. ? PRMT 
type not specified (modified from Pal and Sif 2007). 
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types (Herrmann et al. 2005). Homozygous PRMT1 knockout mice die at embryonic day 
6.5, indicating that protein methylation is required for early postimplantation 
development. However, embryonic cells derived from PRMT1–/–  mice were viable, 
although the PRMT1 expression and activity were dramatically reduced in those cells 
(Pawlak et al. 2000).  
The major targets of PRMT1 are nuclear core histones H3 and H4, and members 
of heterogenous nuclear ribonucleoprotein (hnRNP) family including Src-associated in 
mitosis of 68 kDa (Sam68), hnRNP A1, A2, R and K, mediating RNA processing and 
export (Pal and Sif 2007). The PRMT1 interacts directly with p65 and synergistically 
coactivates transcription complex formation leading to the activation of NF-κB (nuclear 
factor-κB) gene expression (Hassa et al. 2008). The involvement of PRMT1 was also 
observed in the regulation of cellular signal transduction. Methylation of NFAT 
interacting nuclear protein 45 (NIP45) enhanced cytokine production in Th (T helper) 
cells (Mowen et al. 2004). The PRMT1 is also the predominant methyltransferase 
implicated in alterations to the subcellular localization of proteins, for instance, 
posttranslational modification of Sam68 is required for its nuclear localization  
(Cote et al. 2003) and RNA binding activity (Rho et al. 2007). 
Although the methyltransferase activity of PRMT2 has not been demonstrated, 
PRMT2 regulates transcription in vivo by binding a number of hormone receptors (ERα, 
ERβ, PR, TRβ, RARα) in a ligand-independent manner (Qi et al. 2002). Similar to 
PRMT1, PRMT2 is involved in the regulation of NF-κB-dependent gene expression, and 
promotes apoptosis. Studies in mice exposed to normoxic (21% O2) or hypoxic (4% O2) 
conditions confirmed the role of PRMT2 in the development of pulmonary hypertension 
(Yildirim et al. 2006). 
The PRMT3 harbors a characteristic N-terminal zing finger motif, which is 
required for the binding to RNA-associated proteins in extracts from RAT1 fibrobrast 
cells (Frankel and Clarke 2000). The PRMT3 knockout mice are viable, but embryos 
differ in size to wild-type animals, and are characterized by hypomethylation of cellular 
proteins (Swiercz et al. 2007).  
The PRMT4, also known as coactivator-associated arginine methyltransferase 1 
(CARM1), together with PRMT1, acts with a number of transcription factors, further 
regulating gene expression in the cell. The best-known substrates for this 
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methyltransferase are: CARM1 itself, histone H3, HuD, HuR, ILF3, p300/CBP, PABP1 
and TARPP (Pahlich et al. 2006). Heterozogous PRMT4-deficient  mice are normal and 
fertile, whereas homozygous knockout mice die at birth due to abnormalities in lung 
structure, suggesting an important role of PRMT4 in mouse development (Pawlak et al. 
2000). 
Both PRMT5 and PRMT7 belong to the type II class of methyltransferases. 
Symmetric dimethylation by PRMT5 affects many nuclear proteins, including histones 
H4, H2A, H3, SmD1, SmD3, Sm B/B, coilin, LSm4, SPT and the most-investigated 
substrate, MBP (myelin basic protein), indicating nuclear localization of this protein in 
the cell (Bedford and Richard 2005). The PRMT5 participates in RNA processing, as a 
component of 20S methylosome and interaction partner of fibrillarin (Friesen et al. 2001; 
Meister et al. 2001; Pahlich et al. 2006). 
A second type II methyltransferse, PRMT7, contains duplication of conserved PRMT 
motifs and deletion of one SAM-binding domain, leading to loss of enzymatic activity. 
Three substrates for PRMT7 have been identified: histones H2A, H4, and MBP (Lee et 
al. 2005). 
The PRMT6 comprises 375 amino acids, therefore, due to its size, is most similar 
to PRMT1. Nevertheless, its functions differ from PRMT1, since PRMT6 methylates 
DNA polymerase β and the HIV TAT protein (Boulanger et al. 2005; Miranda et al. 
2005; El-Andaloussi et al. 2006). It has been proposed that PRMT6 might modulate 
protein-protein and protein-DNA interaction by methylation of high-mobility group 
proteins (HMGs), HMGA Ia and HMGA Ib (Frankel et al. 2002; Sgarra et al. 2006). 
Interestingly, it has been demonstrated that PRMT6 undergoes automethylation (Frankel 
et al. 2002). 
The most unique methyltransferase is PRMT8. Due to the fact that it possesses  
N-terminal myristoylation signal, PRMT8 is localized to the plasma membrane. The 
comparison of all human methyltransferases demonstrated that PRMT1 and PRMT8 
share the highest degree of identity, including substrate specificity and type I activity 
(Lee et al. 2005). 
Specific substrates as well as biological functions of PRMT9, PRMT10 and 
PRMT11 have not been determined. 
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1.1.2 Role of cellular ADMA 
In vitro and in vivo studies have demonstrated that ADMA, but also L-NMMA, 
inhibits the activity of all three isoforms of nitric oxide synthase (NOS), including neural 
NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS) (Vallance et al. 1992; 
MacAllister et al. 1994). These enzymes are responsible for the formation of nitric oxide 
(NO), a major vasodilator in the cardiovascular system. The reaction requires L-arginine 
as a substrate (figure 1.3). The NO induces vasodilatation, but also acts as an inhibitor of 
LDL (low density lipoprotein) oxidation, platelet aggregation, monocyte and leukocyte 
adhesion to the endothelium, superoxide radical generation, and smooth muscle cell 
proliferation (Garg and Hassid 1989; Kubes et al. 1991; Boger et al. 1995; Hogg et al. 
1995; Boger et al. 1998). Since NOS activity can be inhibited by ADMA, this 
methylarginine may affect all processes in which NO plays significant role. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 ADMA inhibits NOS activity and is metabolized by 
DDAH. L-arginine converts to nitric oxide (NO) and citrulline. 
Optimal enzyme activity requires a broad variety of cofactors: 
flavin adenine dinucleotide (FAD), Haem and tetrahydrobiopterin 
(BH4) and calmodulin (Cal). The ADMA is degraded by  
NG, NG–dimmethylarginine dimethylaminohydrolase (DDAH), 
which is controlled by intracellular NO concentrations (modified 
from Vallance and Leiper 2004). DMA; diamine, FMN; flavin 
mononucleotide, NADPH; nicotinamide adenine dinucleotide 
phosphate. 
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Not only NOS is a target for ADMA. Recently published observations have 
demonstrated that ADMA, as well as L-NMMA and SDMA, can act as a competitor of  
L-arginine for transport through the plasma membrane cationic amino acid transporter 
(y+). This may happen when the intracellular concentration of methylarginine is very 
high (Bogle et al. 1995). Therefore, SDMA can also affect NO production by lowering  
L-arginine bioavailability (Beltowski and Kedra 2006). 
The ADMA can be transported to the neighboring cells and affects their NO generation. 
This interaction has been demonstrated between macrophages and endothelial cells 
(Fickling et al. 1999), suggesting that similar mechanism may occur between other cells 
as endothelium and smooth muscle cells (Vallance and Leiper 2004).   
 
1.1.3 Elimination of ADMA by DDAH 
All methylarginines are released from the body by urinary excretion, but levels of 
ADMA are additionally controlled by enzyme called NGNG–dimethylarginine 
dimethylaminohydrolase (DDAH). Previously published observations revealed that more 
than 90% of ADMA is degraded by this enzyme, resulting in the generation of citrulline 
and dimethylamines (McDermott 1976; Ogawa et al. 1987). The human DDAH gene 
contains an 858-base pair open reading frame encoding a single 285-amino acid protein. 
The DDAH exists in two isoforms: DDHA1 and DDAH2. Although the enzyme activity 
of the two isoforms is similar, the tissue distribution varies between DDAH1 and 
DDAH2. Interestingly, DDAH1 appears to overlap with nNOS expression, whereas 
DDAH2 is mainly expressed in tissue containing eNOS (Leiper et al. 1999; Tran et al. 
2003). 
The DDAH activity might be reversibly inhibited by the S-nitrosylation of cysteine 
residues (figure 1.3). This reaction leads to oxidation of a sulfur atom of the active site 
cysteine, resulting in deactivation of this protein residue. The S-nitrosylation of DDAH 
provides a potential mechanism that reduces NO generation by inactivation of DDAH, 
consequently increasing intracellular ADMA levels, and finally inhibiting NOS activity 
(Leiper et al. 2002). 
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1.2 Alterations to methylarginine metabolism in human 
1.2.1 Human cancer 
Modulation of PRMT expression has already been demonstrated in human cancers 
such as prostate and breast cancer. These forms of tumor are primarily hormone 
dependent. Due to the fact that methyltransferases are known coactivators of nuclear 
receptors, the overexpression of PRMTs in these cancer types should be expected 
(Bedford and Richard 2005). Indeed, studies on human prostate carcinoma revealed 
enhanced levels of PRMT4 in primary prostate tissue specimens, and lowering its 
expression resulted in inhibition of cell proliferation, suggesting that PRMT4 may be 
essential for tumor progression (Majumder et al. 2006). Other studies have demonstrated 
that inhibitors of PRMT4, as well as PRMT1, can suppress estrogen and androgen 
receptor-mediated transcriptional activation (Cheng et al. 2004). In addition, PRMT5 is 
involved in the pathogenesis of breast cancer by inhibiting the expression of tumor 
suppressors (Moggs et al. 2005). The role of this enzyme in tumorigenesis was supported 
by the finding that PRMT5 was overexpressed in gastric carcinoma (Kim et al. 2005). 
 
1.2.2 Viral pathogenesis 
It has been suggested that protein arginine methylation may play an important role 
in viral pathogenesis. The human immunodeficiency virus (HIV) transactivator (TAT) 
protein was identified as the first HIV protein containing arginine residues methylated by 
PRMT6, and inhibition of arginine methylation leads to enhanced HIV gene expression 
(Kwak et al. 2003; Boulanger et al. 2005). While increasing protein methylation may 
offer some protection against HIV infection, inhibition of this protein modification may 
prevent hepatitis delta virus replication (Li et al. 2004). 
 
1.2.3 Multiple sclerosis 
Myelin basic protein is a substrate for PRMT5 and PRMT7, and exibits enhanced 
methylation levels in multiple sclerosis. Although the physiological relevance of this 
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modification is unknown, it has been suggested that the posttranslational modification of 
arginine residues in MBP plays an important role in multiple sclerosis (Kim et al. 2003). 
The explanation might be that methylated MBP serves as autoantigen, similar to 
methylated Sm and coilin in lupus erythomatosus (Carroll 2004).  
  
1.2.4 Abnormal ADMA levels in human disorders 
The accumulation of ADMA has been demonstrated in a wide range of disorders. 
Abnormalities in methylarginine metabolism manifest by altered cellular, as well as 
tissue and urinary ADMA concentration (Tran et al. 2003). The elevated ADMA levels 
have been found, for example, in patients with atherosclerosis (Miyazaki et al. 1999), 
hypercholesterolemia (Boger et al. 1998), muscular dystrophy (Inoue et al. 1979) and 
stroke (Yoo and Lee 2001). 
As ADMA is eliminated from the body by urinary excretion, altered ADMA 
levels were first demonstrated for patients with chronic kidney failure. In those patients, 
the plasma ADMA concentration was increased from 1 to 3 μM, compared to between 
0.4 to 0.7 μM for healthy humans (Vallance et al. 1992). It has been demonstrated that 
there is a relationship between plasma levels and the degree of endothelial dysfunction 
(Cross et al. 2001). Patients who had elevated ADMA levels in plasma also exhibited 
enhanced risk for cardiovascular disorders and higher mortality (Vallance 2001; Zoccali 
et al. 2001). Unfortunately, therapy with L-arginine did not clearly demonstrate a 
beneficial effect on patients with renal failure (Hand et al. 1998; Cross et al. 2001). 
Levels of ADMA are elevated in animal models of type I and type II diabetes, and 
in patients with overt type II diabetes or insulin resistance (Paiva et al. 2003; Xiong et al. 
2003). Glucose can suppress DDAH activity, and this may explain the increased 
methylarginine concentrations observed in this disease (Lin et al. 2002).  
Chronic heart failure (CHR) is characterized by the heart's inability to pump 
sufficient blood to maintain normal circulation. Levels of ADMA are increased in 
patients with CHR and lower ventricular contraction and heart rate (Vallance and Leiper 
2004). There is increasing evidence that systemic administration decreases systemic 
vascular resistance, mean arterial pressure, increases ventricular stroke volume and 
cardiac output (Wu and Meininger 2000). Thus, elevated ADMA levels together with the 
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effect of L-arginine supplementation, suggests a potential role for methylarginine 
metabolism in the pathophysiology of CHR in humans (Vallance and Leiper 2004). 
 
1.3 Pulmonary arterial hypertension 
1.3.1 Characteristics of pulmonary arterial hypertension 
Pulmonary arterial hypertension (PAH) is a severe, progressive and fatal disease 
which is defined as a mean pulmonary arterial pressure higher than 25 mm Hg at rest or 
30 mm Hg during exercise (Puri et al. 2007). It is a rare disorder with an estimated 
prevalence of 1-2 cases per million, and is twice as common in women as in men  
(Martin et al. 2006). 
The common presenting symptom of patients with PAH is dyspnea on exertion. 
Other symptoms such as chest pain, lightheadedness and palpitations may also be 
observed, nevertheless the final diagnosis of PAH may be confirmed only by chest X-ray 
or transthoracic Doppler-echocardiography (Martin et al. 2006). 
  The World Health Organization (WHO) classified PAH according to the etiology 
of various forms of this disease. Thus, PAH has been separated into five categories: 
idiopathic (IPAH), familial (FPAH), associated (APAH) with variety of diseases 
(collagen vascular disease, HIV infection, portal hypertension), associated with 
significant venous or capillary involvement, and  persistent pulmonary hypertension of 
the newborn (Martin et al. 2006). 
With current available therapies, the progression of PAH can not be cured, but 
improvement and quality of life of patients with PAH can be achieved (Chan and 
Loscalzo 2008). Therefore, the understanding of the molecular mechanisms involved in 
the pathogenesis of PAH has become an important issue for scientists studying this 
complex disease.  
 
1.3.2 Histopathological abnormalities 
Pulmonary arterial hypertension is characterized by changes in the structure and 
function of smooth muscle cells, endothelial cells and fibroblasts contributing to vascular 
Introduction  12 
remodeling (figure 1.4), altered tone and vasoreactivity. Two histopathological 
abnormalities contribute greatly to the elevated arterial pressure observed in PAH. Medial 
thickening occurs through the hypertrophy and hyperplasia of smooth muscle cells; and 
second, muscularization of distal vessels occurs due to the proliferation and 
differentiation of fibroblasts and pericytes (Meyrick and Reid 1980; Strange et al. 2002; 
Nicod 2007). 
 
 
 
 
 
 
 
 
 
The plexiform lesion is one of the characteristic pathological abnormalities in 
PAH. It is made up of a monoclonal population of endothelial cells and smooth muscle 
cells. It has been proposed that differentiated and proliferating endothelial cells might 
Donor PAH 
Figure 1.4 Histopathological changes observed in pulmonary 
arterial hypertension (PAH). Pulmonary arterioles in a normal 
patients (left) and in patients with PAH (right) with significantly 
hypertropic tunica medium (modified from Eickelberg and Seeger 
2005).  
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form plexiform lesions, indicating the clear involvement of these cells in the development 
of PAH (Eickelberg and Seeger 2005; Nicod 2007). Endothelial cells may also contribute 
to vascular wall thickening by synthesizing a number of growth factors and vasodilators 
that directly regulate matrix deposition and smooth muscle cell proliferation (Martin et al. 
2006).  
 
1.3.3 Genetic determinants of pulmonary arterial hypertension 
Several observations have indicated that in the pathogenesis of PAH, some 
genetic components are involved that initiate or cause progression of the disease. 
1.3.3.1 The bone morphogenetic protein pathway 
During recent years, genetic discoveries have drawn the attention to bone 
morphogenetic proteins (BMPs) and the BMP receptor II (BMPR-II) (Lane et al. 2000).  
The BMPs are members of the transforming growth factor (TGF)-β family. Their 
involvement in the regulation of cellular processes such as growth, differentiation and 
apoptosis has been previously reported. It has been demonstrated that a number of cell 
types in humans have ability to synthesize and secrete BMPs, for instance, smooth 
muscle cells and endothelial cells (Nohe et al. 2002).  
The BMP receptors play an important role in cell-cell interaction and intracellular 
signal transduction. After binding of BMP to the BMPR-II, BMPR-I is recruited into the 
heteromeric complex, resulting in phosphorylation of cytoplasmic transcription factors, 
called Smads. Phosphorylated Smads bind to common Smads which are required to 
translocate receptor-regulated Smads into the nucleus. Binding of complex-containing 
transcription factors to DNA activates specific gene expression regulating cell 
differentiation and cell proliferation (Massague and Chen 2000).  
Heterozygous mutations of the BMPR-II gene have been found in approximately 
60% of patients with a family history of the disease (familial PAH) and in 20% of 
patients with sporadic IPAH (Newman et al. 2001). Interestingly, genetic disturbances to 
genes encoding BMPR-II led to decreased protein expression, which has been reported in 
patients with idiopathic form of PAH. Recently published studies have involved  
BMPR-II mutations in the modulation of protein-protein interaction. The BMPR-II 
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variants that contain amino acid substitutions present in PAH patients exhibited a reduced 
affinity for receptor for activated protein kinase C (RACK1) resulting in a significant 
increase in PASMC proliferation, which is characteristic of this disorder (Zakrzewicz et 
al. 2007). 
 
1.3.3.2 Activin receptor-like kinase 1 
Defect in genes encoding activin receptor-like kinase (ALK)-1 causes hereditary 
hemorhagic telangiectasia (HHT), an autosomal dominant inherited disease, characterized 
by mucocutaneous telangiectasis, causing gastro-intestinal blood loss. Mutations in the 
ALK-1 gene might cause HHT to develop together with PAH, or PAH alone  
(Trembath et al. 2001).     
 
1.3.3.3 Serotonin 
The last gene known to be implicated in the pathogenesis of PAH is the serotonin 
gene, which encodes a protein which interacts with a specific transporter to enter 
PASMC, and induces cell proliferation. Due to the fact that platelet and plasma  
5-hydroxytryptamine (5-HT, serotonin) levels are increased in clinical hypertension, it 
has been proposed that serotonin transporter gene polymorphisms might be genetic 
determinants of a variety of forms of PAH (Abenhaim et al. 1996; Eddahibi et al. 2002; 
Nicod 2007). 
 
1.3.4 Humoral regulators in pulmonary arterial hypertension 
There is a growing evidence that vasoconstriction and vascular remodeling 
observed in chronic pulmonary hypertension is caused by an imbalance in vasoconstrictor 
and vasodilator activity (figure 1.5). 
1.3.4.1 Prostacyclin 
Prostacyclin (prostaglandin I2, PGI2), a potent vasodilator and an inhibitor of 
platelet aggregation, is produced by endothelial cells. Patients with PAH exhibit an 
imbalance in the local production of PGI2 and thromboxane (arachidonic acid 
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metabolites), and lowered expression of PGI2 synthase (Christman et al. 1992; Tuder et 
al. 1999; Strange et al. 2002) (figure 1.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It has previously been demonstrated that PGI2 has an inhibitory effect on vascular 
smooth muscle cell proliferation and vascular remodeling in vivo (Todaka et al. 1999). 
Pharmacological analogs of PGI2 (iloprost, cicaprost) reduce the growth of distal human 
PASMC. All these findings suggest that a prostacyclin imbalance might markedly 
influence pulmonary vascular tone and structure in PAH (Wharton et al. 2000).   
 
Figure 1.5 Consequences of pulmonary artery endothelial cell 
dysfunction on pulmonary artery smooth muscle cell tone and 
proliferation. Dysfunctional endothelial cells (grey) decrease the 
generation of prostacyclin, nitric oxide (NO) and increase the 
production of endothelin-1 leading to vasoconstriction and 
proliferation of pulmonary smooth muscle cells (orange) (modified 
from Humbert et al. 2004). ETA; ETA receptor, ETB; ETB 
rereceptor, cAMP; cyclic adenosine monophosphate, cGMP; cyclic 
guanosine monophosphate. 
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1.3.4.2 Endothelins 
The endothelins (ET-1, -2, -3) are synthesized from precursors by endothelin-
converting enzymes (ECEs) (Strange et al. 2002). The cells, which are mainly responsible 
for production and release of ET-1 in the lung are endothelial and epithelial cells, as well 
as vascular smooth muscle cells after cytokine stimulation (Woods et al. 1999). 
Endothelin-1 exhibits high binding affinity to the G-protein-coupled receptors ETA 
receptor (ETA) and ETB receptor (ETB), which differ in their distribution pattern in the 
lung. The ETA is predominantly expressed in proximal pulmonary arteries, while ETB 
occurs in vascular smooth muscle cells in distal resistance vessels. Both endothelin 
receptors have a significant impact on vasoconstriction and proliferation (Zamora et al. 
1993; McCulloch et al. 1996) (figure 1.5). 
 
1.3.5 Nitric oxide generation in PAH 
1.3.5.1 Nitric oxide production 
Nitric oxide is one of the major endothelium-derived vasoactive mediators. Nitric 
oxide is produced in the endothelium by endothelial nitric oxide synthase. The NO 
generation results in the activation of soluble guanylate cyclase, which increases cyclic 
GMP (guanosine monophosphate) levels in vascular smooth muscle cells. This activates a 
protein kinase, which leads to the inhibition of calcium influx and decreased calcium-
calmodulin stimulation of myosin light chains. This, in turn, reduces the phosphorylation 
of myosin light chains, lowering smooth muscle tension, resulting in vasodilation  
(Boger and Bode-Boger 2000; Galley and Webster 2004) (figure 1.5). 
Studies with knockout mice have supported the significant impact of eNOS on 
pulmonary vascular homeostasis. Indeed, eNOS-deficient mice exhibit mild pulmonary 
hypertension, under normobaric normoxia, and increased susceptibility to hypoxia-
induced pulmonary hypertension (Fagan et al. 1999; Strange et al. 2002). In contrast, 
overexpression of eNOS in transgenic mice prevents vascular remodeling in the lung 
(Budhiraja et al. 2004). 
Although animal experiments have clearly demonstrated an important role for 
eNOS in vasodilation, results from human studies are not consistent. Patient data have 
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suggested increased, decreased and unchanged expression of eNOS in PAH (Giaid and 
Saleh 1995; Xue and Johns 1995; Tuder et al. 1999). 
 
1.3.5.2 L-arginine content in patients with PAH 
Limitation of L-arginine might modulate NO concentrations in humans. Indeed, 
PAH patients with reported decreased NO levels have lower L-arginine content in their 
serum due to enhanced activity of arginase, an enzyme that converts L-arginine to 
ornithine and urea. Oral L-arginine supplementation reduces pulmonary pressures in 
these patients, but does not completely halt the progression of the disease (Mori and 
Gotoh 2000; Morris et al. 2003). 
  
1.3.6 ADMA metabolism in PAH 
It is well established that ADMA is a naturally occurring inhibitor of eNOS. 
Lowering NO production by blocking eNOS activity, leads to cardiovascular diseases 
such as PAH. In addition, DDAH metabolizes 90% of circulating ADMA. Both enzymes, 
eNOS or DDAH, are known to be involved in human PAH pathogenesis, by regulation of 
ADMA metabolism (figure 1.6). However, it remains unclear whether ADMA is a 
pathophysiologically relevant mediator of pulmonary hypertension (Vallance and Leiper 
2004).   
It has been reported that heterozygous DDAH1-deficient mice accumulate ADMA 
which account for reduced vascular NO signaling, endothelial dysfunction and elevated 
systemic and pulmonary artery pressure. In contrast, transgenic mice overexpressing 
DDAH1 exhibit reduced systolic blood pressure and systemic vascular resistance. These 
observations implicate DDAH1 in preventing pulmonary vascular remodeling (Vallance 
and Leiper 2004). 
  Initial reports on the serum ADMA content in PAH have revealed markedly 
increased ADMA levels in patients compared to matched controls as well as an important 
role for ADMA in the prediction of survival in patients with this disorder (Kielstein et al. 
2005). 
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 Interestingly, elevated levels of methylarginines have also been encountered in 
monocrotaline-treated rats, a well established animal model of pulmonary hypertension 
(Pullamsetti et al. 2005). The DDAH expression observed in both animal and human 
hypertensive lungs supported the theory that modulation of DDAH activity may represent 
a new strategy for the treatment of PAH. 
 
 
 
 
Figure 1.6 Possible roles played by enzymes involved in ADMA 
metabolism in PAH (modified from Pullamsetti et al. 2005). 
PRMT; protein arginine methyltransferase, DDAH; NG, NG–
dimmethylarginine dimethylaminohydrolase, ADMA; asymmetric 
ω-NG, NG-dimethylarginine, NO; nitric oxide, NOS; nitric oxide 
synthase, PAH; pulmonary arterial hypertension. 
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2 Aim of the study 
The implication of protein arginine methylation in human cardiovascular disorders 
has been suggested by previous studies. However, the available data are fragmentary and 
the interplay of methylarginine formation and degradation has not been studied in detail 
so far. Therefore, the expression and activity of methylarginine metabolizing enzymes 
were analyzed in cell culture, mouse organs, and lung homogenates from PAH patients. 
In detail, specific aims of this research were: 
 
1) to develop a novel method for quantitative assessment of free versus protein-
incorporated methylarginine in vitro and in vivo, 
 
2) to assess tissue-specific patterns of protein arginine methylation in the mouse 
cardiovascular system, 
 
3) to analyze the expression and activity of ADMA metabolic enzymes in mouse 
organs, 
  
4) to analyze the protein arginine methyltransferase expression and activity in 
patients suffering from pulmonary arterial hypertension, 
 
5) to applicate an siRNA technology to further investigate the role of PRMT1 in 
pulmonary arterial hypertension. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Equipment 
ABI PRISM 7500 Sequence Detection System  Applied Biosystems, USA 
Cell Culture Incubator; Cytoperm2     Heraeus, Germany 
Chroma SPIN-1000 DEPC-H2O Columns   Biosciences, Clontech, USA 
Developing machine; X Omat 2000     Kodak, USA 
Electrophoresis chambers      Bio-Rad, USA 
Film cassette       Sigma-Aldrich, Germany 
Filter Tip FT: 10, 20, 100, 200, 1000    Greiner Bio-One, Germany 
Filter units 0.22 μm syringe-driven     Millipore, USA 
Freezer -20 °C      Bosch, Germany 
Freezer -40 °C      Kryotec, Germany 
Freezer -80 °C      Heraeus, Germany 
Fridge +4 °C       Bosch, Germany 
Fusion A153601 Reader     Packard Bioscience, Germany  
Gel blotting paper 70 × 100 mm     Bioscience, Germany 
Glass bottles: 250, 500, 1000 ml     Fischer, Germany 
GS-800TM Calibrated Densitometer    Bio-Rad, USA 
HPLC system:  
ASI-100 auto sampler    Dionex, USA 
P680 gradient pump    Dionex, USA 
RF-2000 fluorescence detector  Dionex, USA 
Data acquisition system Chromeleon 6.60 Dionex, USA 
Light microscope Olympus BX51     Olympus, Germany 
µBondapak™ C18 guard column    Waters, USA 
Mini spin centrifuge       Eppendorf, Germany 
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Multifuge centrifuge, 3 s-R      Heraeus, Germany 
Nanodrop®       Peqlab, Germany 
Oasis MCX solid-phase extraction cartridges   Waters, USA 
PCR-thermocycler       MJ Research, USA 
Pipetboy        Eppendorf, Germany 
Pipetmans: P10, P20, P100, P200, P1000    Gilson, France 
Power Supply; Power PAC 300     Bio-Rad, USA 
Petri dish with vents       Greiner Bio-One, Germany 
Pipette tip: 200, 1000 μl,     Sarstedt, Germany 
Pipette tip 10 μl       Gilson, USA 
Quantity One software     Bio-Rad, USA 
Radiographic film X-Omat LS     Sigma-Aldrich, Germany 
Serological pipette: 5, 10, 25, 50 ml    Falcon, USA 
SunFire™ C18 column     Waters, USA 
Single-use syringe      Braun, Germany 
Test tubes: 15, 50 ml       Greiner Bio-One, Germany 
Tissue culture chamber slides     BD Falcon, USA 
Tissue culture dish 100 mm      Greiner Bio-One, Germany 
Tissue culture flask 250 ml      Greiner Bio-One, Germany 
Tissue culture plates: 6, 48 well    Greiner Bio-One, Germany 
Trans blot transfer medium (0.2 μm)    Bio-Rad, USA 
Western blot chambers:  
Mini Trans-Blot     Bio-Rad, USA 
Mini-Protean 3 Cell     Bio-Rad, USA 
Vortex machine       Eppendorf, Germany 
Vacuum-manifold      Millipore, USA 
Vacuum centrifuge      Eppendorf, Germany 
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3.1.2 Reagents 
Acetone       Roth, Germany 
Acetonitrile       Roth, Germany 
Acrylamide solution, Rotiphorese Gel 30   Roth, Germany 
Agarose        Invitrogen, UK 
Albumine, bovine serum     Sigma-Aldrich, Germany 
Ammonium persulphate     Promega, Germany 
Ammonium sulphate       Sigma-Aldrich, Germany  
β-glycerophosphate      Sigma-Aldrich, Germany 
β-mercaptoethanol       Sigma-Aldrich, Germany 
Bromophenol blue       Sigma-Aldrich, Germany 
Calcium chloride       Sigma-Aldrich, Germany 
CompleteTM Protease inhibitor    Roche, Germany 
DEPC water       Roth, Germany 
D-(+)-Glucose       Sigma-Aldrich, Germany 
Dimethyl sulfoxide (DMSO)     Sigma-Aldrich, Germany 
D-MEM medium      Gibco BRL, Germany  
DNA Ladder (1 kb)      Promega, USA 
Ethylendinitrilo-N, N, N´, N´, -tetra-acetic-acid (EDTA)  Promega, USA 
Ethylene glycol-bis (2-amino-ethylether)-N,N,N’,N’ 
-tetraacetic-acid (EGTA)     Sigma-Aldrich, Germany 
Dulbecco’s phosphate buffered saline 10× PAA Laboratories, Austria 
Dulbecco’s phosphate buffered saline 1× PAA Laboratories, Austria 
Ethanol absolute       Riedel-de Haën, Germany 
ECL Plus Western Blotting Detection System  Amersham Biosciences, UK 
Ethidium bromide      Roth, Germany 
Fetal calf serum (FCS)     Gibco BRL, Germany 
Gel extraction kit      Qiagen, Germany 
Glycine       Roth, Germany 
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Hydrochloric acid       Sigma-Aldrich, Germany 
2-(-4-2-hydroxyethyl)-piperazinyl-1-ethansulfonate  
(HEPES)       Sigma-Aldrich, Germany 
[3H]-thymidine      GE HealthCare, UK 
Igepal CA-630       Sigma-Aldrich, Germany 
L-arginine       Sigma-Aldrich, Germany 
Magnesium chloride       Sigma-Aldrich, Germany 
Magnesium sulfate       Sigma-Aldrich, Germany 
MetafecteneTM       Biontex, Germany 
Methanol        Fluka, Germany 
M-MLV reverse transcriptase    Promega, USA 
N,N,N',N'-tetramethyl-ethane-1,2-diamine (TEMED) Bio-Rad, USA 
Oligo(dT)15 Primer      Promega, USA 
Opti-MEM medium       Gibco BRL, Germany 
ortho-phthaldialdehyde (OPA) Grom-chromatography, 
Germany 
PCR Nucleotide Mix      Promega, USA 
Penicillin-streptomycin     PAA Laboratories, Austria 
Potassium acetate       Sigma-Aldrich, Germany 
Potassium borate  Grom-chromatography, 
Germany 
Potassium chloride       Merck, Germany 
Potassium phosphate       Sigma-Aldrich, Germany 
Precision Plus ProteinTM Standards     Bio-Rad, USA 
2-Propanol        Merck, Germany 
QIAprep Spin Miniprep Kit     Qiagen, Germany 
Quick StartTM Bradford Dye Reagent   Bio-Rad, USA 
RNAsin inhibitor      Promega, Germany 
RNeasy Midi Kit      Qiagen, Germany 
Smooth muscle cell medium 2    Promocell, Germany 
Sodium acetate       Sigma-Aldrich, Germany 
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Sodium chloride       Merck, Germany 
Sodium dodecyl sulfate (SDS)    Promega, USA 
Sodium ortho vanadate     Sigma-Aldrich, Germany 
Sodium phosphate       Sigma-Aldrich, Germany 
Sodium sulfate       Merck, Germany 
SuperSignal® West Pico Chemiluminescent Substrate Pierce, USA 
SYBER® Green PCR Kit     Qiagen, Germany 
Trichloroacetic acid      Sigma-Aldrich, Germany 
Tris         Roth, Germany 
Triton X-100        Promega, USA 
Trypsin/EDTA       Gibco BRL, Germany 
Tween 20        Sigma-Aldrich, Germany 
X-treme GENE siRNA transfection reagent   Roche, Germany 
 
3.2 Cells 
 
A549 cell line (human, lung carcinoma), epithelial  DSMZ, Germany 
Human primary pulmonary arterial smooth muscle  
cells (hPASMC)      Promocell, Germany 
 
3.3 Animals 
C57BL/6N mice      Charles River, Germany 
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3.4 Samples from mice 
3.4.1 Broncho-alveolar lavage fluid, serum and tissues 
All animal studies in the project were performed according to the guidelines of the 
University of Giessen and approved by the local authorities (Regierungspräsidium 
Giessen, no. II25.3–19c20–15; GI20/10-Nr.22/2000). Tissue samples were obtained from 
specific pathogen-free female C57BL/6N mice weighing 18-20 g. From mice under 
anesthetic, BALF and serum, were collected and all mouse tissues were surgically 
excised, washed in ice-cold 1 x PBS and frozen in liquid nitrogen for further analyses. 
 
3.5 Samples from human origin 
3.5.1 Lung tissue 
Lung tissue biopsies were obtained from 10 organ donors, mean age 36.4 ± 13.5 
years, six females, four males) and 12 patients with pulmonary arterial hypertension  
(33.3 ± 12.1 years, nine females, three males). The study protocol was approved by the 
Ethics Committee of the Justus-Liebig-University School of Medicine (AZ 31/93). 
Informed consent was obtained from each subject for the study protocol.   
 
3.5.2 Serum and broncho-alveolar lavage fluid 
The group examined consisted of seven volunteers (mean age 37.4 ± 2.1 years, 
three females, four males) who had never smoked and had no history of either cardiac or 
pulmonary disease, and had normal chest X-rays and pulmonary function. Informed 
consent was obtained from each subject for the study protocol. 
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3.6 Methods 
3.6.1 RNA isolation 
The RNA was isolated from cell cultures according to the manufacture’s 
instructions provided with the RNeasy Midi Kit. 
 
3.6.2 RNA and DNA determination 
The concentration of isolated RNA or DNA was measured according to a protocol from 
Peqlab by applying 1.5 μl of the sample to a Nanodrop® spectrophotometer. 
 
3.6.3 Reverse transcription reaction 
Reverse transcriptase polymerase chain reaction (RT-PCR) is an enzymatic 
reaction during which reverse transcriptase (RT) generates cDNA complementary to 
RNA. 
Each reaction was performed with 500 ng of RNA and 4 μl of oligo(dT)15  
(100 μg/ml) primers and was diluted with RNAse free water to a final volume of 10 μl. 
The sample was mixed in a PCR tube and heated (70 °C) for 5 min to allow primers to 
bind specifically to polyA tail of mRNA. The reaction was cooled on ice for 5 min, and 
later the rest of required reagents were combined. 
 
RT-Mix: 
Components Volume Final 
concentration 
5× RT Buffer 5 μl 1 × 
10 mM dNTP mix 0.5 μl 0.2 mM 
RNAsin inhibitor (1 U/μl)  0.5 μl 0.5 U 
MMLV Reverse transcriptase  
(1 U/μl) 
0.5 μl 0.5 U 
RNAse free water 8.5 μl not applicable 
 
Materials and Methods  27 
 
The reaction was performed at 40 °C for 60 min and completed at 70 °C for 15 min. The 
resulting complementary DNA (cDNA) was further used for polymerase chain reaction or 
stored at -20 °C. 
 
3.6.4 Polymerase chain reaction 
Polymerase chain reaction (PCR) is an enzymatic reaction, carried out by DNA 
polymerase and permits the amplification from selected fragments of genomic DNA. 
Product specificity is determined by the DNA primers used in the reaction. 
 
3.6.4.1 Semi-quantitative PCR 
The reaction was performed according to a protocol from the Go Taq® Flexi 
DNA polymerase kit, and all components were combined as follows: 
 
PCR-mix: 
Components Volume 
 
Final 
concentration 
5× PCR Buffer (free MgCl2 free) 10 μl 1 × 
10 mM dNTP mix 1 μl 0.2 mM 
25 mM MgCl2 2 μl 1 mM 
10 μM forward primer* 1 μl 0.2 mM 
10 μM reverse primer* 1 μl 0.2 mM 
DNA (template) 1 μl not applicable 
GoTaq® Flexi DNA polymerase 
(5U/μl) 
0.25 μl  1.25 U 
*The primers are listed in Table 6.1 
 
All components were mixed in a 0.5 ml tube and the final volume was adjusted with 
distilled, autoclaved water up to 50 μl. The sample was transferred to a  
PCR thermocycler and denatured for 3 min at 94 °C. The reaction was performed for 36 
cycles. Each cycle contained three steps: denaturation (separation of double-stranded 
DNA), annealing (binding of primers to specific region of DNA), and elongation 
(extending of generated product). The steps were carried out as follows: 
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PCR program: 
Step Temperature Time 
Denaturation 95 °C 1 min 
Annealing 60 °C 1 min 30 s 
Elongation 72 °C 2 min 
 
The reaction was completed by a final extension step at 72 °C for 30 min. 
The sample was further analyzed by DNA gel electrophoresis or stored at -20 °C.  
 
3.6.4.2 Real-time PCR 
Real-time PCR is a variation of the polymerase chain reaction, which is 
commonly used for amplification and quantification of specific fragments of cDNA. 
During the reaction, fluorescence dye (SYBER® Green) binds to amplify double-stranded 
DNA and a signal is detected after each cycle of PCR reaction. The level of fluorescence 
is proportional to the amount of amplified DNA. 
The reaction was performed according to a protocol from the SYBER® Green PCR kit 
using a Sequence Detection System 7500 Fast from Applied Biosystems. All components 
were combined as follows: 
 
Real-time PCR mix: 
Components Valume Final 
concentration 
Platinum® Syber® Green qPCR 
SuperMix-UDG 
13 μl 1 × 
50 mM MgCl2 1 μl 2 mM 
10 μM forward primer* 0.5 μl 0.2 mM 
10 μM reverse primer* 0.5 μl 0.2 mM 
DNA template 1 μl not applicable 
*The list of all primers is described in Table 6.1 
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The sample was filled up with distilled, autoclaved water to final volume of 25 μl. The 
real-time PCR was performed for 45 cycles as follows: 
 
Real-time PCR program: 
Step Temperature Time 
Denaturation 95 °C 5 s 
Annealing 60 °C 5 s 
Extension 72 °C 30 s 
 
Human porphobilinogen deaminase (PBGD), an equally expressed gene, served as a 
control (reference gene) for all real-time PCR reactions. Relative transcripts abundance of 
targeted genes was expressed in ΔCt values (ΔCt = Ct reference – Ct target). The proper size 
of the amplicons was assessed by agarose gel electrophoresis.  
 
3.6.5 Gel electrophoresis 
Gel electrophoresis is a technique which allows the separation of either nucleic 
acids (DNA, RNA) or proteins according to their physical properties (size, electric charge 
and other physical properties). 
 
3.6.5.1 DNA gel electrophoresis 
For preparation of 1% agarose gels, agarose was dissolved in 1 × Tris-acetate-
EDTA (TAE) buffer containing 0.5 μg/ml ethidium bromide, a fluorescent intercalating 
dye. Before loading onto the gel, DNA samples were mixed 5:1 with 6 × agarose gel-
loading buffer. Electrophoresis was performed at 100 V, in 1 × TAE buffer, for 45-60 
min. Separated nucleic acids were visualized with short wavelength ultraviolet light  
(λ 257 nm).  
 
1 × TAE buffer:  
    40 mM Tris acetate, pH 8.0 
1 mM EDTA, pH 8.0 
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6 × agarose gel-loading buffer: 
0.025% (w/v) bromophenol blue 
40% (w/v) sucrose 
 
3.6.5.2 Protein gel electrophoresis 
To separate proteins, according to their size, SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed. The 10% resolving gel mixture was poured 
between two glass plates with spacers between, and allowed to polymerize. The stacking 
gel was poured on the top of resolving gel, and the comb was inserted in to the gel to 
form the wells. Before sample was loaded on to gel, protein samples were mixed with  
10 × SDS gel-loading buffer and heated at 95 °C for 7 min. Electrophoresis was carried 
out in 1 × SDS-running buffer at 120 V for 1 h. 
 
5% stacking gel: 
5% acrylamide/bisacrylamide 
125 mM Tris-HCl, pH 6.8 
0.1% SDS (w/v) 
0.1% APS (w/v) 
0.1% TEMED (v/v) 
 
10% resolving gel: 
10% acrylamide/bisacrylamide 
375 mM Tris-HCl, pH 6.8 
0.1% SDS (w/v) 
0.1% APS (w/v) 
0.1% TEMED (v/v) 
 
10 × SDS-loading buffer: 
625 mM Tris-HCl, pH 6.8 
50% (v/v) glycerol 
20% (w/v) SDS 
9% (v/v) β-mercaptoethanol 
0.3% (w/v) bromophenol blue 
 
1 x SDS running buffer: 
25 mM Tris 
250 mM Glycine 
0.1% (w/v) SDS 
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3.6.6 Protein isolation 
In order to isolate proteins from cell culture and tissue samples, two alternative 
methods were applied.  
 
3.6.6.1 Protein isolation from cell culture 
Cells were washed twice with ice-cold 1 × phosphate-buffered saline (PBS). The 
same buffer was applied to cell monolayers (100 μl/cm2), and cells were detached from 
culture plates by scraping, and transferred to 1.5 ml tube. After centrifugation for 3 min at 
3000 g, the pellet was resuspended in 100 μl of cell-lysis buffer. The cell lysate was 
incubated for 1 h on ice and centrifuged at 16000 g for 15 min. The resulting supernatant 
was used as a crude cell extract, and stored at -20 °C. 
 
1 × PBS, pH 7.4: 
0.08% (m/v) NaCl 
0.02% (m/v) KCl 
0.115%  (m/v) Na2HPO4 · 2H2O 
0.02% (m/v) KH2PO4 · 2H2O 
 
Cell-lysis buffer: 
20 mM Tris-HCl, pH 7.5 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
0.5% Igepal CA-630 
2 mM Na3VO4 * 
Complete™, protease inhibitor mix * 
*Added immediately prior to homogenization 
 
3.6.6.2 Protein isolation from tissue 
Mouse or human tissue was homogenized in liquid nitrogen followed by addition 
of ice-cold tissue lysis buffer. Tissue lysate was then passed 3 × through a 0.9 mm needle 
fitted to a RNAse-free syringe. Homogenized tissue was incubated for 1 h on ice and 
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centrifuged for 15 min at 16000 g. The resulting supernatant was used as a crude tissue 
extract and stored at -20 °C. 
 
Tissue lysis buffer: 
20 mM Tris-HCl, pH 7.5 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
1% (v/v) Triton X-100 
2 mM Na3VO4 * 
Complete™, protease inhibitor mix * 
*Added immediately prior to homogenization 
 
3.6.6.3 TCA precipitation 
Trichloroacetic acid (TCA) precipitation is a method commonly used for protein 
concentration and purification. It allows the separation of macromolecules, such as 
proteins, from other organic compounds (fats, amino and nucleic acids), present in the 
protein crude extract. 
Proteins were precipitated by mixing 100 μl of tissue/cell extract with an equal volume of 
20% (v/v) trichloroacetic acid for 20 min on ice. After centrifugation at 16000 g for  
12 min, the supernatants were removed and the protein pellets were washed with 100 μl 
ice-cold acetone for 60 min at -20 °C. The suspension was centrifuged at 16000 g for  
12 min and resulting protein pellet was dissolved in 100 μl of distilled water. 
 
3.6.6.4 Hydrolysis 
Total hydrolysis of precipitated protein fractions (20 μl) was achieved by gas-
phase hydrolysis with 100 μl of 6 M HCl at 110 °C for 16 h. Samples were dried by use 
of a vacuum centrifuge and stored at -20 °C until further analyzed. 
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3.6.6.5 Protein determination 
Protein determination was performed using Quick StartTM Bradford Dye Reagent 
and measured spectrophotometrically on a Fusion A153601 Reader. The method is based 
on chemical, colorimetric reaction between Coomassie Brilliant Blue G-250 dye and 
aromatic amino acids residues (Bradford 1976). The color change is proportional to the 
amount of protein in the sample, and can be measured as an absorbance by 
spectrophotometer. The Bradford method requires a calibration curve to be generated 
each time the assay is run before unknown protein concentrations can be determined. 
Sample (10 µl) was mixed in a 96-well plate with 200 μl of Quick StartTM Bradford Dye 
reagent. Reaction mixtures were incubated for 15 min at room temperature. The 
absorbance was measured at 570 nm. For preparation of calibration, five dilutions  
(0.05-0.4 μg/μl) of bovine serum albumin (BSA) were used. 
 
3.6.7 Subcellular fractionation 
To obtain nuclear and cytosolic fractions, cells were washed twice with ice-cold 
1× PBS, scraped in PBS and collected by centrifugation at 3000 g for 3 min. Cells were 
resuspended in ice-cold hypotonic lysis buffer and incubated on ice for 10 min. After 
incubation, nuclear and cytosolic fractions were separated by centrifugation at 5000 g for 
5 min. The supernatant served as the cytosolic fraction, and was stored at -20 °C for 
further investigation. Hypertonic lysis buffer was added to the pellet, mixed and 
incubated on ice for 45 min. Nuclear soluble compounds were separated by centrifugation 
at 12000 g for 10 min, 4 °C. The nuclear fraction was stored at -20 °C for further 
analysis. 
 
Hypotonic-lysis buffer: 
20 mM HEPES, pH 7.9 
10 mM KCl 
1 mM EDTA 
1 mM EGTA 
0.2% (v/v) NP-40 
10% (v/v) glycerol 
2 mM Na3VO4 * 
Complete™, protease inhibitor mix * 
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Hypertonic-lysis buffer: 
20 mM HEPES, pH 7.9 
10 mM KCl 
420 mM NaCl 
1 mM EDTA 
1 mM EGTA 
20% (v/v) glycerol 
2 mM Na3VO4 * 
Complete™, protease inhibitor mix * 
*Added immediately prior to homogenization 
 
3.6.8 Analysis of basic amino acids 
3.6.8.1 Isolation of basic amino acids 
All procedures were performed as previously described (Bulau et al. 2006). 
Tissue/cell extracts and amino acid hydrolysates were subjected to crude fractionation on 
Oasis MCX cation exchange solid-phase extraction (SPE) columns. For tissue/cell 
extracts, 50 μl of each sample was combined with 10 μl of L-homoarginine (4 pmol/ μl) 
as internal standard and adjusted to a final volume of 1 ml with PBS. Amino acid 
hydrolysates were dissolved in 1 ml PBS. All conditioning, washing, and elution steps 
were performed on a vacuum manifold with a capacity of 10 columns, at a flow rate of 
0.5 ml/min. The SPE columns were conditioned with 2 ml of eluent solution followed by 
2 ml of PBS prior to sample application. Samples were passed through the SPE cartridges 
and the contaminating components were rinsed with 2 ml of 0.1 M HCl followed by 2 ml 
methanol. Basic amino acids were eluted with 1 ml of H2O/methanol/ammonia  
(45/50/5; v/v). The samples were dried by use of vacuum centrifuge at 65 °C. Eluates 
were redissolved in 230 μl of distilled water and centrifuged at 14000 g for 2 min. 
 
3.6.8.2 Derivatization with OPA reagent 
Amino acids form highly fluorescence adducts when reacted with  
ortho-phthaldialdehyde (OPA) under basic conditions. The products of this reaction 
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exhibit optimal excitation at 330 nm and emission at 450 nm and can be quantified by 
fluorescence detection.  
All procedures were performed as previously described (Bulau et al. 2006). The 
OPA was freshly prepared in potassium borate buffer, according to the manufacturer’s 
instructions. Sample (50 µl) was combined with 62.5 µl of OPA, immediately transferred 
to the auto sampler, and injected exactly after 2 min. 
 
3.6.8.3 Chromatographic separation by HPLC 
Quantification of amino acids was performed on a HPLC system with the data 
acquisition system Chromeleon 6.60. Separation was performed according to a method 
previously described (Bulau et al. 2006; Bulau et al. 2007). Fluorescent amino acid 
derivatives were separated on a SunFireTM C18 column (4.6 × 150 mm; 3.5 µm particle 
size; 100 Å pore size) with a µBondapakTM C18 guard column at 25 °C and a flow rate of 
1.1 ml/min. After injecting 125 µl of the sample, separation was performed under 
isocratic conditions with HPLC running buffer as solvent. The isocratic conditions were 
maintained for 25 min. In order to elute strongly-bound compounds, the column was 
flushed with 50% (v/v) acetonitrile for 15 min and reequilibrated under isocratic 
conditions for 25 min prior to the next injection. Fluorescent derivatives were detected at 
excitation and emission wavelengths of 330 and 450 nm, respectively. L-arginine, 
ADMA and SDMA were quantified by two separated steps. For detection of ADMA and 
SDMA, the gain of the detector was switched to a hundred-fold higher sensitivity. 
 
HPLC running buffer (pH 6.8): 
8.8% (v/v) acetonitrile 
25 mM potassium phosphate 
25 mM sodium phosphate 
 
3.6.8.4 DDAH activity assay 
The activity of DDAH was assayed by directly measuring the amount of ADMA 
metabolized by the enzyme. 
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For tissue extracts and serum, 25 μl of each sample was combined with ADMA/SDMA 
solution (500 pmol/μl each) and adjusted to a final volume of 0.5 ml with 0.1 M sodium 
phosphate buffer (pH 6.5). After incubation for 2 h at 37 °C, samples were directly 
subjected to crude fractionation on Oasis MCX cartridges, HPLC separation and 
fluorescence detection. As assay blank, ADMA and SDMA from the crude tissue extracts 
were directly quantified. 
 
3.6.9 Western blot analysis 
Western blot analysis allows the visualization of levels of candidate proteins using 
specific antibodies for recognition. 
 
3.6.9.1 Immunoblotting 
Proteins separated by SDS-PAGE were transferred from the polyacrylamide gel to 
a polyvinylidene difluoride (PVDF) membrane. The membrane was first activated in 
100% methanol, and transfer was performed in transfer buffer at 100 V for 1 h. 
 
Transfer buffer (pH 7.4): 
24 mM Tris 
193 mM glycine 
10% (v/v) methanol 
 
3.6.9.2 Protein visualization 
The membrane was incubated in blocking solution for 1 h followed by incubation 
with appropriate primary antibodies in blocking buffer at 4 °C overnight.* Then, the 
membrane was washed 3 × with washing buffer and  incubated with horseradish 
proxidase (HRP) labeled secondary antibodies for 1 h at room temperature. The 
membrane was washed 5 × for 10 min. Proteins were detected using chemiluminescence 
by Enhanced Chemiluminescent Immunoblotting System and membrane was exposed to 
radiographic film. 
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To apply second antibody, the membrane was incubated in stripping buffer for  
10 min, washed in washing buffer for 5 min, and protein visualization was performed as 
previously described. 
*Primary and secondary antibodies are listed in Tables 6.2 and 6.3 
 
Blocking buffer: 
5% (w/v) non-fat dry milk 
1 × PBS 
0.1% (v/v) Tween-20 
 
Washing buffer: 
1 × PBS 
0.1% (v/v) Tween-20 
 
Stripping buffer: 
62.5 mM Tris-HCl, pH 6.8 
2% (w/v) SDS 
100 mM β-mercaptoethanol 
 
 
3.6.9.3 Densitometric analysis 
Densitometric analysis of autoradiographies was performed using a GS-800 
Calibrated Densitometer and 1-D analysis software Quantity One (Bio-Rad, USA). 
Protein expression was normalized to the appropriate house-keeping protein used in the 
experiment. 
 
3.6.10 Immunohistochemistry 
To elucidate the localization of proteins of interest in lung tissue, 
immunohistochemical analysis was performed using a Histostain-SP Kit. Whole lung 
sections (3µm) were deparaffinized in xylene 3 × for 10 min followed by dehydration in a 
graded alcohol series. Antigen retrieval was performed in citrate buffer (pH 6.0) for 20 
min at 100 °C. Slides were washed 2 × for 5 min in 1 × PBS. To block activity of 
endogenous peroxidase, sections were immersed in 3% (v/v) H2O2 for 20 min. Sections 
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were incubated with blocking reagent (provided with the kit) for 10 min at room 
temperature to prevent non-specific binding. Primary antibodies *were applied to sections 
and incubated at 4 °C overnight. Sections were washed with 1 × PBS for 5 min and 
incubated with secondary biotinylated antibodies followed by streptavidin-conjugated 
enzyme and chromogenic reagent, separately for 10 min. Slides were developed for 5 min 
with diaminobenzidine (DAB) and counterstained with Mayers hematoxylin. Finally, 
sections were mounted using and examined using Olympus BX51 microscope. 
*Primary antibodies are listed in Table 6.2 
 
3.6.11 Cell culture 
3.6.11.1 Culture of mammalian cells 
3.6.11.1.1 A549 cells 
Cells were grown in tissue culture flasks in D-MEM medium containing  
10% (v/v) heat-inactivated fetal calf serum (FCS) at 37 °C, 5% CO2, 95-100% humidity. 
The cell line was passaged when attaining 80-90% confluence. During passaging, cells 
were washed with 1 × PBS and incubated with 3 ml of Trypsin/EDTA solution for 3 min 
at 37 °C, after which 7 ml of D-MEM medium was added. Cells were transferred to new 
tissue culture flasks after 1:5 dilution with medium.  
 
3.6.11.1.2 Pulmonary artery smooth muscle cells 
  Pulmonary arterial smooth cells (PASMC) were grown in tissue culture flasks in 
smooth muscle cell medium 2 at 37 °C, 5% CO2, 95-100% humidity. The cell line was 
passaged when attaining 80-90% confluence. During passaging, cells were washed with  
1 × PBS and incubated with 3 ml of trypsin solution for 3 min at 37 °C after which 7 ml 
of medium was added. Cells were transferred to new tissue culture flasks after 1:5 
dilution with medium. 
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Trypsin solution: 
0.25% (m/v) Trypsin 
1.23 g/ml EDTA 
 
3.6.11.2 Transient transfection 
3.6.11.2.1 siRNA technique 
The PASMC were plated onto 6-well tissue culture dishes in smooth muscle cell 
medium 2 to obtain 60-70% confluence. After 16 h, medium was exchanged and cells 
were incubated in 1:50 diluted medium (starvation conditions) for 4-5 h. In order to 
downregulate PRMT1, siRNA sequence* against this gene was used. To exclude possible 
non-specific effects of PRMT1 siRNA, the experiment was controlled by the use of a 
universal siRNA negative control commercially available from Ambion. Transfection 
reagent (X-treme GENE silencing or Metafectane) was mixed with Opti-MEM medium 
and incubated at room temperature for 5 min. Afterwards, siRNA was added, gently 
mixed and left for 20 min. Cells were transfected using transfection complexes, incubated 
4-5 h followed by addition of fresh smooth muscle cell medium 2. Cells were harvested 
for 16-48 h, washed with 1 × PBS and stored at -20 °C for further analysis. 
*List of siRNAs is shown in Table 6.4 
 
3.6.11.3 Proliferation assay 
A proliferation assay quantifies cell proliferation. When assessed by tritium 
incorporation it is based on the measurement of radioactivity incorporated into the DNA 
during cell growth. 
The PASMC were grown on 48-well tissue culture plates in smooth muscle cell medium 
2. After transfection, using siRNA, and incubation for 16-48 h, cells were pulsed with  
0.6 μCi of [3H]-thymidine for 4-5 h. Cells were washed 5 × with 1 × PBS and solubilized 
in 300 μl of 0.5 M NaOH. After overnight incubation at 4 °C, the contents of each well 
were combined with 8 ml of scintillation fluid and radioactive counts were measured in a 
liquid scintillation counter.  
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4 Results 
4.1 Development of a method for quantification of 
methylarginine content in biological samples 
To study protein-incorporated versus free-cellular methylarginine levels either in 
tissue or in cell culture extracts, a novel HPLC-based technique was developed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Strategy for the quantification of protein-
incorporated and free-cellular L-Arg, ADMA and SDMA in 
human and mouse tissue homogenates. ADMA; asymmetric  
ω-NG, NG-dimethylarginine, RP-HPLC; reverse phase-high 
performance liquid chromatography.
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Crude tissue homogenates were subjected to SPE followed by derivatization of 
basic amino acids with OPA (ortho-phthaldialdehyde) reagent and further analyzed by 
RP-HPLC (figure 4.1).  
The quantification of protein-incorporated methylarginines additionally required 
protein precipitation and protein hydrolysis of prior to cation exchange SPE, reaction 
with OPA and chromatographic separation, as outlined in figure 4.1. 
 
4.1.1 Standard curves and calibration 
For method validation, calibration was performed using six standards spanning 
the varied concentration range for L-Arg, L-NMMA, ADMA and SDMA.  
Standard solutions were combined with 15 pmol of internal standard  
L-homoarginine (L-H Arg) and subjected to SPE, derivatization and chromatography as 
described in the Materials and Methods. Calibration curves were analyzed by plotting the 
peak area ratios of analyte (L-Arg, L-NMMA, ADMA, SDMA) to the area of the internal 
standard versus analyte quantity and resulted in linear coefficients (R2) of 0.9981, 0.9992, 
0.9989, 0.9998 and 0.9989 for L-Arg, L-NMMA, L-H Arg, ADMA and SDMA, 
respectively (figure 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results  42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
. 
. 
. 
. 
. 
 
R2 = 0.9981 
Figure 4.2 Linear regression of standard curves. Calibration was 
performed using the concentration range of 1.5 to 450 pmol (60 nM 
to 18 μM) for L-Arg; 0.15 to 45 pmol (6 nM to 1.8 μM) for  
L-NMMA and ADMA and 0.09 to 9 pmol (3.6 nM to 0.36 μM) for 
SDMA. L-NMMA; ω-NG-monomethylarginine, L-H Arg; ω-NG-
homoarginine, ADMA; asymmetric ω-NG, NG-dimethylarginine, 
SDMA; ω-NG, N' G-dimethylarginine. 
R2 = 0.9992 
R2 = 0.9989 R2 = 0.9998 
R2 = 0,9989 
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4.1.2 Recovery 
In order to validate the recovery of methylated L-Arg derivatives after protein 
precipitation and protein hydrolysis standard solution containing L-Arg, L-NMMA,  
L-H Arg, ADMA and SDMA were subjected to acid hydrolysis followed by SPE and 
chromatographic separation. As illustrated in table 4.1, all compound recoveries  
were ≥84 %. To analyze the application of L-H Arg as internal standard, relative 
recoveries were calculated and defined as the absolute recovery divided by the recovery 
of internal standard. The relative recoveries for all amino acids were almost 100%  
(table 4.1).  
 
 
 
 
 
 
 
 Absolute recovery Relative recovery 
L-Arg 84.56 ± 2.50% 96.78 ± 2.67% 
L-NMMA 84.45 ± 3.83% 96.61 ± 2.68% 
L-H Arg 87.46 ± 4.45% Not applicable 
ADMA 88.08 ± 4.08% 100.74 ± 1.87% 
SDMA 87.83 ± 5.06% 100.42 ± 2.69% 
 
 
To further confirm that protein precipitation does not alter the levels of methylated 
protein, MBP from bovine brain was analyzed. The MBP is a well-characterized protein, 
which contains monomethylargin and symmetrically dimethylarginines. In order to 
measure extent of protein methylation, MBP was subjected to protein precipitation 
followed by acid hydrolysis.  
 
 
Tabele 4.1 Absolute and relative recovery of analytes subjected to 
protein hydrolysis followed by SPE and chromatography.  
Absolute recovery was calculated as percentage of peak area obtained 
after RP-HPLC. Relative recovery was determined as percentage of 
the recovery of L-H Arg. Data are presented as means ± SD, n = 6.  
L-NMMA; ω-NG-monomethylarginine, L-H Arg; ω-NG-homoarginine, 
ADMA; asymmetric ω-NG, NG-dimethylarginine, SDMA; ω-NG, N' G-
dimethylarginine. 
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Quantification of L-Arg, L-NMMA and SDMA in MBP after direct hydrolysis with or 
without protein precipitation suggested no significant differences in relative 
methylarginine content (figure 4.3). Asymmetric dimethylation of MBP arginine residues 
was not detected. 
 
4.1.3 Dynamic metabolism of L-Arg, ADMA and SDMA under 
proteosome inhibition 
To prove that the HPLC method was suitable for the observation of dynamic 
changes in protein arginine methylation in biological samples, A549 cells were cultured 
with or without the proteosome inhibitor MG-132 for 2 h. Inhibition of protein 
degradation led to a significant increase in L-Arg levels in protein hydrolysates  
(58.2 ± 3.7 versus 47.3 ± 5.6 nmol/mg protein), as illustrated in figure 4.4 A, with a 
Figure 4.3 Protein precipitation does not alter protein 
methylation. L-Arg, L-NMMA and SDMA content in amino acid 
hydrolysates of purified MBP is similar before and after 
precipitation. Data are presented as mean ± SD in pmol, n = 6. 
MBP; myelin basic protein, SD; standard deviation, L-NMMA; ω-
NG-monomethylarginine, L-H Arg; ω-NG-homoarginine, SDMA; ω-
NG, N' G-dimethylarginine. 
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concomitant decrease of free L-Arg levels (3.01 ± 0.3 versus 4.14 ± 0.4 nmol/mg protein), 
as illustrated in figure 4.4 B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
 
Figure 4.4 Degree of protein methylation in protein 
hydrolysates (A) and crude extracts (B) in A549 cells after 
treatment with a proteosome inhibitor. The A549 cells were 
cultured in absence or presence of MG-132 (5 μM) for 2 h. The 
concentration of L-Arg, ADMA and SDMA was assesed by HPLC. 
Data are presented as mean ± SD, n = 4,* P < 0.05, two-tailed t-
test. SD; standard deviation, HPLC; high performance liquid 
chromatography, ADMA; asymmetric ω-NG, NG-dimethylarginine, 
SDMA; ω-NG, N' G-dimethylarginine. 
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Treatment with MG-132 significantly reduced free-cellular ADMA levels  
(0.015 ± 0.003 versus 0.022 ± 0.003 nmol/mg protein; figure 4.4 B), but also significantly 
decreased ADMA levels in protein hydrolysates (0.22 ± 0.05 versus 0.41 ± 0.12 nmol/mg 
protein), as illustrated in figure 4.4 A. Significant differences in SDMA concentrations 
were not observed. 
 
4.2 Analysis of ADMA metabolism 
4.2.1 Methylarginine content in mouse organs of the 
cardiovascular system 
In order to assess tissue-specific protein arginine methylation, HPLC-based 
quantification of protein-incorporated and free methylarginines was employed. The  
L-Arg, ADMA and SDMA levels were assessed in mouse homogenates from lung, heart, 
kidney and liver. 
 
4.2.1.1 Protein-incorporated L-arginine, ADMA and SDMA 
To analyze whether different organs exhibited distinct methylation characteristics, 
L-Arg and its methylated forms were measured in protein hydrolysates and crude extracts 
derived from mouse organs of cardiovascular system. As figure 4.5 illustrates, lung 
proteins exhibited a four-fold higher degree of asymmetrical and a two-fold higher degree 
of symmetrical arginine methylation (ADMA: 4.23 ± 2.19, SDMA 0.37 ± 0.17 nmol/mg 
protein) compared with heart (ADMA:1.11 ± 0.53, SDMA 0.22 ± 0.007 nmol/mg 
protein), kidney (ADMA: 1.41 ± 0.26, SDMA 0.27 ± 0.003 nmol/mg protein) or liver 
(ADMA: 1.04 ± 0.42, SDMA: 0.21 ± 0.007 nmol/mg protein) hydrolysates, which 
exhibited almost identical levels of protein-incorporated ADMA and SDMA. The  
L-arginine concentrations did not exhibit any significant differences between samples. 
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4.2.1.2 Free-cellular methylarginines 
Levels of free cellular ADMA and SDMA were similar in the lung  
(ADMA: 0.010 ± 0.004, SDMA 0.0017 ± 0.0005 nmol/mg protein) and heart  
(ADMA: 0.014 ± 0.004, SDMA 0.0026 ± 0.005 nmol/mg protein); while the kidney 
(ADMA: 0.118 ± 0.04, SDMA 0.033 ± 0.012 nmol/mg protein) and the liver  
(ADMA: 0.088 ± 0.02, SDMA 0.011 ± 0.003 nmol/mg protein) exhibited significantly 
higher concentrations of both methylarginines, as illustrated in figure 4.6. 
 
 
 
 
 
 
 . 
*
Figure 4.5 Concentration of protein-incorporated L-Arg, 
ADMA and SDMA in mouse lung, heart, kidney and liver. Data 
are presented as mean ± SD, n = 6, * P < 0.05, one-way ANOVA, 
lung versus all tissues. SD; standard deviation, ANOVA; analysis of 
variance, ADMA; asymmetric ω-NG, NG-dimethylarginine, SDMA; 
ω-NG, N' G-dimethylarginine. 
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4.2.2 L-Arg, ADMA and SDMA in serum and BALF 
Enhanced levels of protein-incorporated ADMA and SDMA observed in the 
mouse lung might reflect the occurrence of the methylarginines, either in mouse BALF or 
serum. To examine levels of methylarginines in biological fluids and to analyze  
species-specific content of protein arginine methylation, levels of L-Arg, ADMA and 
SDMA in serum and BALF from mouse as well as human were assessed. 
 
4.2.2.1 Concentration of L-arginine derivatives in mouse and human serum 
The ADMA levels in mouse serum were significantly higher when compared to 
human serum (0.91± 0.18 versus 0.42 ± 0.06 μM). SDMA (0.3 ± 0.15 versus  
0.42 ± 0.7 μM) exhibited lower concentrations in mouse serum compared to human 
serum. No significant differences were observed for of L-Arg (112.39 ± 17.78 versus  
69.51 ± 11.92 μM), as illustrated in figure 4.7 A. Moreover, ratios of ADMA to SDMA as 
well as ratio of L-Arg to SDMA in mouse serum were higher than in human serum 
. 
*
* **
**
Figure 4.6 Concentration of free-cellular L-Arg, ADMA and 
SDMA in mouse lung, heart, kidney and liver. Data are presented 
as mean ± SD, n = 6, * P < 0.05; kidney versus lung and heart, **  
P < 0.05, liver versus lung and heart, one-way ANOVA. 
ANOVA;analysis of variance, SD; standard deviation, ADMA; 
asymmetric ω-NG, NG-dimethylarginine, SDMA; ω-NG, N'G-
dimethylarginine. 
 
. 
. 
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(ADMA/SDMA: 3.5 ± 1.2 versus 1.04 ± 0.24, L-Arg/SDMA: 428.37 ± 146.79 versus 
168.01 ± 23.62; figure 4.7 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
*
*
Figure 4.7 Concentration (A) and ratios (B) of methylarginines 
in mouse and human serum. Data are presented as mean ± SD, 
mouse: n = 10, human: n = 7, * P < 0.001, two-tailed t-test. SD; 
standard deviation, L-NMMA; ω-NG-monomethylarginine, ADMA; 
asymmetric ω-NG, NG-dimethylarginine, SDMA; ω-NG, N'G-
dimethylarginine. 
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4.2.2.2 Methylargine content in human and mouse BALF 
Both ADMA and SDMA were detected in mouse and human BALF. As 
illustrated in figure 4.8 A, the ADMA concentration was significantly higher in the 
mouse compared to the human (0.053 ± 0.02 versus 0.03 ± 0.013 pmol/mg protein), 
whereas the opposite situation was observed for SDMA (0.0102 ± 0.004 versus  
0.031 ± 0.006 pmol/mg protein).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
*
*
. 
. 
B. 
*
*
Figure 4.8 Concentration (A) and ratios (B) of methylarginines 
in mouse and human BALF. Data are presented as mean ± SD, 
mouse: n = 10, human: n = 7, * P < 0.001, two-tailed t-test.  
L-NMMA; ω-NG-monomethylarginine, ADMA; asymmetric ω-NG, 
NG-dimethylarginine, SDMA; ω-NG, N' G-dimethylarginine, BALF; 
broncho-alveolar lavage fluid, SD; standard deviation. 
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The L-Arg levels did not differ between mouse and human (6.07 ± 1.88 versus 
4.81 ± 1.71 pmol/mg protein). Interestingly, the ratios of ADMA to SDMA (4.23 ± 0.81 
and 0.8684 ± 0.2659), L-Arg to ADMA (108.34 ± 20.05 and 162.9 ± 35.7) and L-Arg to 
SDMA (475.83 ± 174 and 142.14 ± 49.47) in BALF were similar to those observed in 
serum. Taken together, mouse and human tissues displayed different methylarginine 
concentrations and ratios, both in the serum and the BALF. In contrast, both species 
demonstrated a similar methylarginine distribution between serum and BALF.  
 
4.2.3 Expression of PRMTs in mouse lung, heart, liver and kidney 
The ADMA is produced through methylation of protein arginine residues by 
PRMT type I enzymes (Bedford and Richard 2005). To further investigate whether 
enhanced levels of protein-incorporated ADMA observed in the mouse lung correlated 
with increased PRMT expression, western blot followed by densitometric analysis were 
performed on crude mouse extracts. As illustrated in figure 4.9 A, expression levels of 
both type I and type II PRMTs varied in the mouse lung, heart, kidney and liver.  
Densitometric analysis (figure 4.9 B) revealed that mouse lungs expressed 
significantly higher levels of PRMT1, PRMT2 and PRMT6 compared to other organs. 
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Figure 4.9 Expression pattern of PRMT enzymes in mouse 
tissues. Western blot (A) was performed with 20 μg protein from 
crude organ extracts from mice followed by densitometric analysis 
(B). In panel B, data are presented as mean ± SD, * P < 0.05, lung 
versus all tissues, one-way ANOVA. SD; standard deviation, 
ANOVA; analysis of variance 
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4.2.4 Analysis of ADMA degradation 
Cellular ADMA occuring in mammals can be degraded and converted to citrulline 
and mono- or di-methylamines by DDAH (Bedford and Richard 2005). To study  
tissue-specific ADMA degradation, western blot analysis of DDAH expression and 
HPLC measurement of DDAH activity were performed. 
4.2.4.1 Expression of mouse DDAH isoforms 
 To examine the expression levels of DDAH isoforms, western blot analysis was 
performed on crude extracts derived from mouse lung, heart, kidney and liver (figure 
4.10 A). Densitometric analysis revealed that DDAH1 was significantly more expressed 
in the kidney and liver, compared to the lung, while in the heart, DDAH1 was not 
detected (figure 4.10 B, left panel). In contrast, DDAH2 was equally expressed in the 
liver, lung and heart, whereas significantly lower expression of this isoform was observed 
in kidney lysates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Liver Lung Heart Kidney 
DDAH2 
DDAH1 
A. 
Figure 4.10 Expression of DDAH isoforms in mouse tissues. 
Western blot analysis (A) was performed with 20 μg protein from 
crude organ extracts from mice followed by densitometric analysis 
(B). Data are presented as mean ± SD;* P < 0.05, kidney and liver 
versus  heart and lung, ** P < 0.05, kidney versus all tissues, one-
way ANOVA. ANOVA; analysis of variance, DDAH;  
NG,NG–dimmethylarginine dimethylaminohydrolase, SD; standard 
deviation HPLC; high performance liquid chromatography, 
ADMA;. asymmetric ω-NG, NG-dimethylarginine. 
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4.2.4.2 Tissue-specific activity of DDAH 
To investigate whether expression of DDAH isoforms was correlated with tissue-
specific degradation of ADMA, studies of DDAH activity were performed. To study 
enzyme activity in vitro, mouse protein extracts were incubated with a standard solution 
containing ADMA and SDMA and subjected to HPLC-based method for quantification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
ADMA 
SDMA
L-Arg 
B. 
**
*
Figure 4.11 DDAH activity in mouse tissues.  HPLC 
chromatograms of combined standard containing 15 pmol ADMA 
and SDMA (A upper panel) and from crude lung extract incubated 
with an identical amount of combined standard (A, lower panel). 
Enzymatic degradation of 0.75 pmol of ADMA in 25 μl of lung, 
heart, kidney and liver extracts. Data are presented as mean ± SD,  
n = 5, * P < 0.05, kidney versus all tissues, one-way ANOVA; ** 
P < 0.05, liver versus lung, two-tailed t-test. ANOVA; analysis of 
variance, SD; standard deviation HPLC; high performance liquid 
chromatography, ADMA; asymmetric ω-NG, NG-dimethylarginine,  
DDAH; NG,NG–dimmethylarginine dimethylaminohydrolase, 
SDMA; ω-NG, N' G-dimethylarginine. 
. 
. 
. 
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Measurement of DDAH activity was based on the determination of tissue-specific 
ADMA degradation (nmol ADMA/mg tissue protein) as illustrated in figure 4.11 A. As 
figure 4.11 B indicates, kidney lysates exhibited the highest DDAH activity compared 
with those from the liver and lung. Moreover, degradation was found to be significantly 
higher in the liver versus the lung. The ADMA degradation was not detected in heart 
lysates and serum. Significant SDMA degradation was not observed in any tissue 
investigated. 
 
4.3 Protein arginine methylation in pulmonary arterial 
hypertension 
4.3.1 Methylarginine content in tissue lung homogenates from 
PAH patients 
To analyze whether protein arginine methylation and cellular ADMA metabolism 
is altered in patients with pulmonary arterial hypertension, protein-incorporated versus 
free cellular methylarginine levels were assessed in lung homogenates from PAH patients 
and healthy donors. 
4.3.1.1 Protein-incorporated L-Arg, ADMA and SDMA 
Proteins were isolated from human lung tissue and crude extracts were subjected 
to protein precipitation followed by acid hydrolysis (as described in the Materials and 
Methods 1.1.1.2). Chromatographic analysis revealed that L-Arg (PAH: 131.48 ± 48.15 
nmol/mg protein; Donor: 162.370 ± 52.45 nmol/mg protein) and SDMA levels  
(PAH: 0.099 ± 0.039 versus Donor: 0.131 ± 0.1 nmol/mg protein) did not differ 
significantly, whereas significant reduction in protein-incorporated ADMA concentration 
(PAH: 0.545 ± 0.226 versus Donor: 0.846 ± 0.358 nmol/mg protein) was observed in the 
lung homogenates from PAH patients compared to healthy donors, as illustrated in  
figure 4.12. 
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4.3.1.2 Free-cellular methylarginines 
In contrast to protein-incorporated methylarginine, significantly higher levels of 
free-cellular SDMA (PAH: 0.018 ± 0.006 versus Donor: 0.009 ± 0.002 nmol/mg protein) 
were observed in PAH patients compared to donors. The L-Arg (PAH: 4.97 ± 3.55 versus 
Donor: 4.31 ± 1.32 nmol/mg protein) and ADMA levels (PAH: 0.027 ± 0.021 versus 
Donor: 0.028 ± 0.015 nmol/mg protein) did not differ significantly (figure 4.13). 
 
L-Arg ADMA SDMA 
*
Figure 4.12 Box plots of protein-incorporated L-Arg, ADMA 
and SDMA levels in the lung tissue homogenates from PAH 
patients and healthy donors. The box represents the 25th and 75th 
percentile range of scores and the bar within the box represents the 
median. The verticale represents SD; PAH: n = 11, Donor: n = 10,  
* P < 0.05; two-tailed t-test. SD; standard deviation, asymmetric  
ω-NG, NG-dimethylarginin, SDMA; ω-NG, N' G-dimethylarginine. 
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4.3.2 Expression of PRMTs in the lungs from PAH patients and 
healthy donors 
In order to elucidate whether the decreased concentration of protein-incorporated 
ADMA observed in the lung of PAH patients correlats with reduced expression of type I 
PRMTs, western blot analysis was performed (figure 4.14 A). Analysis of PRMT1-6 by 
L-Arg ADMA SDMA 
*
Figure 4.13 Box plots of free-cellular L-Arg, ADMA and SDMA 
levels in the lung tissue homogenates from PAH patients and 
healthy controls. The box represents the 25th and 75th percentile 
range of scores and the bar within the box represents the median. 
The vertical represents SD; PAH: n = 11, Donor: n = 10,  
* P < 0.05, two-tailed t-test. PAH; pulmonary arterial hypertension, 
SD; standard deviation, asymmetric ω-NG, NG-dimethylarginin, 
SDMA; ω-NG, N' G-dimethylarginine. 
.
.
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densitometry revealed reduced expression of type I PRMTs (PRMT1, PRMT3, PRMT6) 
in the lung homogenates from PAH patients versus healthy donors. Importantly, PRMT1 
was significantly less expressed in PAH lung tissue compared with donors  
(figure 4.14 B). 
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Figure 4.14 Expression of PRMTs in the lung homogenates 
derived from PAH patients and healthy donors. Western blot 
analysis (A) was performed with 20 μg protein from human lung 
extracts followed by densitometric analysis (B). CDK4 served as 
loading control. Data are presented as mean ± SEM, * P < 0.05; 
two-tailed t-test. SEM; standard error of the mean, PRMT; protein 
arginine methyltransferase. 
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4.3.3 Western blot analysis of asymmetric dimethylated proteins in 
lung homogenates 
To further analyze differences in protein-incorporated methylarginine levels and 
to examine whether down-regulation of type I PRMTs observed in PAH patients has a 
strong impact on the methylation of specific proteins, western blot analysis was 
performed. For this purpose, the ADMA specific antibody ASYM24 was used. An 
alteration in the methylation pattern of asymmetric dimethylated proteins was observed in 
the PAH patients compared to healthy subjects (figure 4.15). Importantly, significant 
differences in the degree of methylation were observed among proteins at the size 
between 50 and 75 kDa and at around 25 kDa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Analysis of asymmetric dimethylated proteins in  
PAH (n=8) and donor (n=8) lung homogenates.  Protein extracts 
(20µg) were subjected to western blot analysis with an ASYM24 
antibody. An asteriks indicates proteins with altered degree of 
asymmetric dimethylation. β-actin served as a loading control. 
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4.3.4 Immunohistochemical analysis of lung sections 
In order to analyze whether PRMT1 was localized to particular human cell types, 
immunohistochemistry was performed on donor and PAH patient lung sections. The 
PRMT1 staining was detected mainly in PASMC of human lungs, as evident in  
figure 4.16. The expression pattern and localization of PRMT1 did not differ between 
PAH patients and healthy subjects. The α-SMA staining served as a marker for PASMC 
localization in the lung sections.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.16 Localization of PRMT1 in the human lung sections.  
Lung sections were obtained from PAH patients and transplanted 
healthy donors. Data are representative for at least three 
independent samples from at least three different patients or donors. 
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4.3.5 Subcellular fractionation of proteins from human PASMC 
  To support our previous observations from immunohistochemical analysis and 
also to elucidate the cellular compartmentalization of PRMT1, subcellular fractionation 
of proteins from PASMC isolated from healthy donors was performed. Western blot 
analysis indicated that PRMT1 was localized in the cytosol and the nucleus, whereas 
higher levels were detected in the nucleus with concomitantly increased asymmetric 
dimethylation of proteins revealed by the ASYM24 antibodies. To examine the purity and 
enrichment of cellular fractions, western blot analysis was performed. Lamin A/C served 
as a specific marker for nuclear compartment, while purity of cytosolic fraction was 
assessed by determination of tubulin (figue 4.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 Subcellular fractionation of human PASMC. 10 μg 
of nuclear (N) and cytosolic (C) fractions were subjected to western 
blot analysis with antibodies against PRMT1, ASYM24,  
Lamin A/C and tubulin. 
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4.3.6 PRMT1 silencing in PASMC 
To study whether decreased protein-incorporated ADMA levels, as observed in 
PAH patients, might alter PASMC proliferation, a hallmark of PAH pathogenesis, 
knockdown of PRMT1 in PASMC, followed by the assessment of PASMC proliferation, 
was performed. 
   
4.3.6.1 Optimalization of siRNA transfection 
To reduce expression of PRMT1 in PASMC, an siRNA sequence directed against 
PRMT1 mRNA was used. The PASMC are characterized by low transfection efficiency. 
To optimize the transfection protocol, two transfection reagents were examined. 
The PASMC were transfected with siRNA either using Metafectene or X-treme GENE 
siRNA transfection reagent, and the efficiency of down-regulation was assessed by 
analyzing mRNA levels of PRMT1 by real-time PCR. Surprisingly, after transfection 
with siRNA and Metafectene, a significant reduction of PRMT1 expression was not 
observed, either at a siRNA concentration of 50 nM or 100 nM (figure 4.18 A) compared 
to transfection with negative control siRNA. Altered levels of the gene of interest in 
PASMC were already observed after transfection using 50 nM siRNA and X-treme 
GENE siRNA transfection reagent (figure 4.18 B left panel), whereas a higher dose of 
PRMT1 siRNA increased the effect of silencing. After 12 h, 24 h and 36 h, PRMT1 
expression was significantly reduced using 100 nM siRNA and the X-treme GENE 
siRNA transfection reagent (figure 4.18 B, right panel). 
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A. 
Figure 4.18 Optimization of PRMT1 knockdown in PASMC. 
The PRMT1 mRNA levels were assesed by real-time PCR. For 
optimization, two transfection reagents were used: Metafectene at a  
final concentration of 50 nM (A, left panel) and 100 nM (A, right 
panel) and the X-treme GENE siRNA transfection reagent, at a  
final concentration of 50 nM (B, left panel) and 100 nM (B, right 
panel). Data are presented as mean ± SEM, n = 3,* P < 0.05, two-
tailed t-test. 
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4.3.6.2 Specificity of PRMT1 knockdown in PASMC 
To analyze the specificity of PRMT1 silencing, and to examine whether PRMT1 
siRNA might alter the expression of other members of the PRMT family, the mRNA 
levels of PRMT4, a PRMT1 homolog, were assessed by real-time PCR and western blot 
analysis. The mRNA as well as protein levels of PRMT4 were not affected in PASMC by 
treatment with 100 nM siRNA against PRMT1 (figure 4.19 A, B). In addition, the highest 
reduction in PRMT1 expression at the protein level was observed after 36 and 48 h after 
transfection, as illustrated in figure 4.19 B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19 PRMT1 siRNA did not affect mRNA and protein 
levels of PRMT4. The PRMT4 mRNA and protein levels in 
PASMC were assesed by real-time PCR (A) and western blot 
analysis (B).  
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4.3.6.3 Effect of reduced PRMT1 expression on cell proliferation 
  To assess whether alterations to PRMT1 expression would affect PASMC 
proliferation, [H3]-thymidine incorporation, using PASMC transfected with siRNA 
directed against PRMT1, was performed. As figure 4.20 illustrates, knockdown of 
PRMT1 in PASMC resulted in significant enhanced PASMC proliferation compared to 
negative control siRNA-treated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
Figure 4.20 Increased PASMC proliferation after transfection 
with siRNA directed against PRMT1. The proliferation of 
PASMC was analyzed by [H3]-thymidine incorporation assay. Data 
are presented as mean ± SEM; n = 4,* P < 0.05, two-tailed t-test. 
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5 Discussion 
5.1 Protein arginine methylation in the cardiovascular 
system 
5.1.1 Quantitative assessment of free versus protein-incorporated 
methylarginine in vitro and in vivo 
To date, L-Arg, L-NMMA, ADMA and SDMA have been determined by enzyme-
linked immunosorbent assay (ELISA) (Valtonen et al. 2005), high-performance liquid 
chromatography (HPLC) (Heresztyn et al. 2004), capillary electrophoresis (CE) (Causse 
et al. 2000), and liquid chromatography/mass spectrometry (LC/MS) (Pi et al. 2000; 
Vishwanathan et al. 2000; Teerlink et al. 2002; Huang et al. 2004). However, while these 
approaches are suited to the assessment of methylarginine in biological fluids, such as 
plasma, urine or cerebrospinal fluid, they do not allow the quantification of protein 
arginine methylation in the proteome of biological samples. Therefore, an approach for 
the simultaneous quantification of free and protein-incorporated L-Arg, L-NMMA, 
ADMA, and SDMA in cellular and tissue protein extracts was developed. This method 
entailed the isolation of cellular proteins by precipitation and hydrolysis, 
isolation/purification of methylarginines by SPE, derivatization with OPA, and finally 
RP-HPLC separation with fluorescence detection (figure 4.1). 
Since this detection method relies on the quantification of methylated arginines 
after protein precipitation and acid hydrolysis, the approach was validated by assessing 
the amount of methylated arginines before and after protein hydrolysis using a standard 
solution of L-Arg, L-NMMA, L-H Arg, ADMA, and SDMA. For all components, the 
recovery rates were greater than 80%. Using the calculated recovery of the internal 
standard L-H Arg the relative recovery for each component was close to 100%, 
demonstrating that the use of L-H Arg as an internal standard ensures precision equal to 
that obtained with L-NMMA (Teerlink et al. 2002; Heresztyn et al. 2004). 
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Using this assay, the detection limit for all arginine forms was approximately  
100 fmol (0.003 μM in crude extracts, based on a signal-to-noise ratio of 3:1), which is 
comparable to other HPLC methods with fluorescence detection (Teerlink et al. 2002; 
Heresztyn et al. 2004) and with LC/MS-based approaches (Huang et al. 2004). 
To confirm that the protein precipitation procedure used did not selectively enrich 
or deplete specific (methylated) arginines, the extent of arginine methylation was 
measured in a well-characterized purified protein, MBP. The recovery of L-Arg,  
L-NMMA, and SDMA in amino acid hydrolysates of MBP from bovine brain did not 
change after protein precipitation. Approximately 2% of arginine residues in MBP were 
monomethylated, while symmetric dimethylation occurred in approximately 1.5%. 
Asymmetric dimethylation of arginine residues was not detected, which is in agreement 
with a previous study on the characterization of MBP methylation (Deibler and 
Martenson 1973). This indicates that the precipitation procedure did not selectively 
enrich or deplete specific mono- and/or symmetric dimethylated proteins, thus allowing 
accurate quantification of methylarginines in protein precipitates. 
In order to show that the described method is suitable for monitoring dynamic 
changes in arginine methylation patterns in biologically relevant samples, A549 epithelial 
cells, cultured under different conditions, were assayed. Specifically, the impact of 
protein degradation on the amount of methylated arginines was analyzed in the absence 
or presence of the proteosome inhibitor MG-132. Inhibition of the proteosome led to an 
expected increase of L-Arg levels in protein hydrolysates, with a concomitant decrease in 
free L-Arg levels, suggesting decreased protein breakdown. Interestingly, a strong 
reduction in free ADMA, as well as in protein-incorporated ADMA levels was observed 
after MG-132 treatment, while SDMA levels in the same samples did not change. This 
led to selective changes in the arginine/ADMA, arginine/SDMA, and ADMA/SDMA 
ratios of protein-incorporated methylarginine. Therefore, these data suggest that the 
application of the proteosome inhibitor results in the specific inhibition of type I PRMT 
activity without affecting type II PRMT activity. Current and future work will therefore 
strive to understand the mechanisms that regulate PRMT activity via the proteosome 
pathway. 
Discussion  68 
 
In conclusion, a novel method for the accurate quantification of arginine methylation in 
complex biological samples was developed. 
 
5.1.2 Analysis of methylarginine metabolism in the cardiovascular 
system 
To date, the interplay between methylarginine synthesis and degradation in vivo 
has not been described. Thus, PRMT and DDAH activity in mouse lung, heart, liver, and 
kidney homogenates was determined. To this end, HPLC-based quantification of  
protein-incorporated and free methylarginine was employed, combined with 
immunoblotting and ADMA degradation assays, for the assessment of tissue-specific 
patterns of arginine methylation. 
Arginine methylation of proteins is catalyzed by the action of protein arginine 
methylatransferases. Type I enzymes exhibit variable tissue distribution in humans, 
which correlates with the localization of specific target proteins (Wada et al. 2002; 
Boisvert et al. 2003). In the cardiovascular system, PRMT expression has been only 
reported in the human heart, endothelial cells and smooth muscle cells (Vallance and 
Leiper 2004). 
Initially, the present study clearly demonstrated the presence of protein arginine 
methyltransferases in the mouse lung, heart, liver and kidney. The mouse lung exhibited 
significantly higher expression of type I PRMTs (PRMT1, PRMT2, PRMT6) compared 
to the heart, kidney and liver.  
To elucidate whether the increased pulmonary expression of type I PRMTs 
correlated with increased asymmetrical dimethylation of lung proteins, protein hydrolysis 
of tissue proteins and HPLC analysis were performed. In lung protein hydrolysates, 
arginine residues exhibited an almost four-fold higher degree of asymmetrical and  
two-fold higher degree of symmetrical dimethylation, compared with arginine residues 
from heart, kidney, and liver tissue. Free cellular methylarginine levels are dependent 
upon PRMT activity, the rate of protein degradation, the rates of ADMA metabolism by 
DDAHs, degradation of ADMA and SDMA by pyruvate aminotransferase, and the rates 
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of active methylarginine uptake and release. Similar free cellular ADMA and SDMA 
levels were found in the lung and heart, whereas the kidney and liver exhibited 
significantly higher concentrations for of dimethylarginines. Kidney lysates exhibited the 
highest levels of both dimethylarginines. Because kidney proteins did not display a higher 
degree of protein-incorporated methylarginine, the increased ADMA and SDMA levels 
may be a result of active renal methylarginine uptake, as suggested in previously 
published studies (Vallance et al. 1992; MacAllister et al. 1996; Al Banchaabouchi et al. 
2000). Kidney homogenates exhibited significantly higher DDAH1 expression and 
ADMA degradation activity compared with liver, lung, or heart homogenates, suggesting 
that the kidney provides the main route for the clearance and metabolic conversion of 
circulating methylarginines. 
Moreover, kidney lysates displayed the highest capacity for ADMA degradation, 
although DDAH2 expression was significantly lower than that observed in the liver, lung, 
or heart. Furthermore, no significant degradation of SDMA (as a consequence of 
pyruvate aminotransferase activity) was observed. These findings suggest that renal 
metabolism of ADMA is due to the metabolic action of DDAH1 and not DDAH2 and 
pyruvate aminotransferase. This is the first report on the direct characterization of 
methylarginine metabolism in the liver. Liver lysates displayed four- to eight-fold higher 
levels of free cellular ADMA and SDMA compared with the lung and heart. Because 
liver proteins did not exhibit a higher degree of protein-incorporated methylarginine, the 
increased ADMA and SDMA levels may be a result of active hepatic methylarginine 
uptake by the y+ transporter, as suggested in previously published studies (Siroen et al. 
2004; Siroen et al. 2005). Liver lysates also exhibited significantly higher DDAH1 
expression and ADMA degradation activity than did lysates from lung and heart tissue. A 
previously published study on the characterization of ADMA clearance in rat plasma 
after nephrectomy has suggested that ADMA does not require the kidney for its 
elimination from the plasma (Carello et al. 2006). Moreover, a transplanted liver graft is 
capable of clearing circulating ADMA in human patients (Siroen et al. 2004). Thus, these 
data suggest that the liver provides an alternative route for the clearance and metabolic 
conversion of circulating ADMA. Together, kidney and liver tissues exhibited a high 
Discussion  70 
 
capacity for ADMA degradation, supporting the idea that both organs provide 
complementary routes for clearance and metabolic conversion of circulating ADMA.  
Compared with the heart, pulmonary expression of PRMTs was significantly 
increased and correlated with enhanced asymmetrical and symmetrical dimethylation of 
proteins in the lung. In contrast, similar levels of free cellular ADMA and SDMA were 
observed in the lung and heart. Lung homogenates exhibited DDAH1 expression and 
ADMA degradation activity, which was not detected at all in heart lysates, suggesting 
that the lung is capable of metabolic conversion of free cellular methylarginine. Heart 
lysates did not display a capacity for ADMA degradation, although their DDAH2 
expression was slightly higher than those of lung lysates. Therefore, relevant pulmonary 
degradation of ADMA is a result of DDAH1 activity, whereas no contribution of 
DDAH2 is evident. Furthermore, ADMA and also SDMA were detected in mouse and 
human BAL fluid. The BAL fluid of mouse and human exhibited an ADMA/SDMA ratio 
is similar to the ratio observed in the respective sera, suggesting that the similar levels are 
a result of diffusion through paracellular spaces. Circulating ADMA levels are raised in 
patients with pulmonary hypertension and in experimental models of pulmonary 
hypertension (Arrigoni et al. 2003; Millatt et al. 2003; Kielstein et al. 2005; Pullamsetti et 
al. 2005). In the rat model of chronic hypoxia-induced pulmonary hypertension, the effect 
was caused by a decreased expression and activity of DDAH1 (Millatt et al. 2003). Thus, 
the overall pulmonary ADMA output reflects a balance of PRMT activity, rates of protein 
turnover, intracellular DDAH1 activity, and active extrusion from the cell. The relative 
contribution of each component remains to be determined, but the salient findings of the 
present investigation can be summarized as: 1) pulmonary expression of type I PRMTs 
was correlated with enhanced protein arginine methylation of the lung proteome;  
2) pulmonary ADMA degradation was undertaken by DDAH1; and 3) BAL fluid and 
serum exhibited almost identical ADMA/SDMA ratios. Together, these observations 
suggest that methylarginine metabolism by the lung significantly contributes to 
circulating ADMA and SDMA levels. 
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5.2 Analysis of protein arginine methylation in pulmonary 
arterial hypertension 
5.2.1 Lung methylarginine content of patients with pulmonary 
arterial hypertension 
Studies have reported elevated plasma levels of ADMA in patients with 
pulmonary arterial hypertension (Kielstein et al. 2005; Pullamsetti et al. 2005). However, 
other investigators have not detected any changes in plasma methylargine content, 
suggesting the involvement of alternative mechanisms, as such increased arginase 
activity, to the pathogenesis of PAH (Xu et al. 2004). Nevertheless, there is growing 
evidence that pulmonary vascular remodeling and endothelial dysfunction observed in 
chronic hypertension are influenced by ADMA metabolism (Strange et al. 2002; 
Valkonen et al. 2005). Initially, the methylarginine content of lungs from PAH patients 
was analyzed. Tissue homogenates from PAH lungs exhibited significantly lower  
protein-incorporated ADMA levels compared to lungs from healthy donors, whereas 
SDMA levels were not changed. The observed reduction of ADMA concentration in lung 
protein hydrolysates was probably caused by impaired type I PRMT expression as 
PRMT1, PRMT3, and PRMT6 expression was significantly reduced in PAH patients.  
In contrast, free ADMA content was similar in lung crude extracts from PAH 
patients compared to healthy donors, demonstrating that free cellular ADMA levels are 
not lowered as a consequence of reduced type I PRMT expression. A previously 
published study has demonstrated markedly reduced lung DDAH expression in PAH 
patients (Pullamsetti et al. 2005). Therefore, the free cellular concentration of asymmetric 
dimethylarginine might remain unchanged due to less degradation by DDAH.  
Symmetric dimethylarginine is implicated in endothelial dysfunction, which 
characterizes pulmonary hypertension. This L-Arg analog inhibits the y+ transporter that 
mediates the intracellular uptake of L-Arg causing lowered NO production (Closs et al. 
1997; Kielstein et al. 2006). In addition, SDMA is not metabolized by DDAH enzyme, 
therefore, intracellular SDMA levels, generated by proteolysis of methylated proteins, 
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might have a direct impact on plasma levels (Palm et al. 2007). This study has 
demonstrated that the free cellular SDMA concentration was two-fold higher in PAH 
patients compared to healthy donors. These data are consistent with previously published 
reports, which demonstrated elevated plasma levels of SDMA in patients with PAH, as 
well as in monocrotaline-treated rats, suggesting that increased SDMA may contribute to 
prolonged pulmonary vasoconstriction and lung vascular remodeling (Pullamsetti et al. 
2005). 
 
5.2.2 Analysis of asymmetric dimethylated proteins in PAH 
compared to healthy lungs 
Studies using the ASYM24 antibody, which recognizes asymmetric dimethylated 
proteins, confirmed that PAH patients exhibit a reduction in protein arginine methylation 
(Boisvert et al. 2003; Cote et al. 2003; Robin-Lespinasse et al. 2007). The greatest 
spectrum of methylation has been observed in 50 to 75 kDa proteins.  
A well-characterized PRMT target is Sam68, a nuclear protein with an apparent 
molecular mass of 68 kDa (Babic et al. 2004). Posttranslational protein modifications of 
Sam68, such as acetylation (Babic et al. 2004), phosphorylation (Najib et al. 2005) and 
sumoylation (Babic et al. 2006) have been described. Interestingly, phosphorylation of 
this protein by Src kinase promotes cell proliferation (Lukong et al. 2005). However, the 
involvement of Sam68 methylation in the regulation of cell proliferation has not been 
demonstrated to date. Lung homogenates from PAH patients exhibited reduced levels of 
asymmetric dimethylation of some type I PRMT targets, suggesting that methylation of 
Sam68 might be impaired. Thus, it would be of interest to elucidate whether methylation 
of Sam68 regulates cellular processes, which are connected to development of PAH, for 
instance smooth muscle cell proliferation.  
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5.2.3 Analysis of PRMT1 localization in the human lung 
5.2.3.1 Immunohistochemical analysis of PRMT1 tissue localization 
In the cardiovascular system, type I PRMTs are expressed in the heart, smooth 
muscle cells and endothelial cells (Vallance and Leiper 2004), whereas studies on chronic 
hypoxia-induced pulmonary hypertension have demonstrated localization of PRMT1 
primarily in the lung airway and type II epithelial cells (Yildirim et al. 2006). In the 
present study, PRMT1 localization was characterized in the lungs of patients with PAH 
and healthy donors. Staining of lung specimens localized PRMT1 to PASMC, which is 
consistent with previous published observations, suggesting the expression of all type I 
PRMTs in vascular cells (Vallance and Leiper 2004). The expression pattern and 
localization of PRMT1 did not differ between lungs of patients suffering from PAH and 
donor lungs.  
 
5.2.3.2 Cellular compartmentalization of PRMT1 in PASMC 
Subcellular fractionation of human PASMC derived from healthy subjects 
revealed predominant nuclear localization of PRMT1, but PRMT1 was also observed in 
the cytosol. The well-characterized PRMT1 targets are nuclear core histones and  
members of hnRNP family, which mediate RNA processing and import from the nucleus 
(Bedford and Richard 2005; Passos et al. 2006). However, previous studies have 
demonstrated that PRMT1 localization in human embronic kidney 293 cells was six-fold 
more abundant in the cytoplasm than in the nucleus (Herrmann et al. 2005). In addition, 
PRMT1 was identified as a interaction partner of cytoplasmic domain IFNAR1 chain of 
the α, β interferon receptor, suggesting its localization in the cytosolic compartment 
(Abramovich et al. 1997). Thus, most known substrate proteins for PRMT1 are nuclear, 
but the enzyme is not exclusivly located in the nucleus (Herrmann et al. 2005). As 
suggested in previously published studies, PRMT1 is a dynamic protein and its cellular 
localization depends on cell type and experimental conditions. For instance, after 
inhibition of methylation by periodate-oxidized adenosine (Adox), PRMT1 accumulates 
in the nucleus of human embronic kidney 293 cells (Herrmann et al. 2005). Taken 
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together, these data confirm previously published observations, and demonstrate both 
nuclear and cytosolic PRMT1 localization in human PASMC. 
 
5.2.4 Functional effects of transient PRMT1 knockout on smooth 
muscle cell proliferation 
Pulmonary arterial hypertension is characterized by increased PASMC 
proliferation, which causes thickening of the pulmonary vasculature, which subsequently 
reduces the inner diameter of the lumen of pulmonary arteries, increases pulmonary 
vascular resistance, and raises pulmonary arterial pressure (PAP) (Smith et al. 2005). 
Many experimental therapeutic strategies for PAH target molecular mechanism that 
regulate smooth muscle cell growth.      
The PRMT1 accounts for the generation of approximately 85% of asymmetric 
arginine dimethylation in mammals (Tang et al. 2000), suggesting that alterations to 
PRMT1 expression and activity might significantly affect total cellular protein arginine 
methylation and processes regulated by this posttranslational modification. As reduced 
PRMT1 expression and protein arginine methylation were observed in lung homogenates 
of PAH patients, the questions of whether down-regulation of PRMT1 expression might 
affect human PASMC growth was addressed. Interestingly, abrogation of PRMT1 
expression by siRNA treatment resulted in significantly increased proliferation of 
PASMC.  
Although previous studies have suggested that altered ADMA levels may regulate 
the expression of genes involved in cell proliferation (Smith et al. 2005), this is the first 
report indicating a direct involvement of PRMT1 in the progression of  pulmonary 
vascular remodeling controlled by PASMC.  
Protein arginine methylation is implicated in the alteration of protein-protein 
interactions (Pahlich et al. 2006). A well-known PRMT1 substrate is hnRNP K, a nuclear 
protein, which regulates RNA processing in the cell. Methylation of arginine residues by 
PRMT1 reduces hnRNP K interaction with the tyrosine kinase c-Src, resulting in reduced 
phosphorylation of hnRNP K (Ostareck-Lederer et al. 2006). Since phosphorylation of 
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other RNA-binding proteins, like Sam68, is implicated in the regulation of cell 
proliferation (Lukong et al. 2005), the methylation of regulatory proteins by PRMT1 
might modulate PASMC proliferation.  
In recent years, apoptosis has been linked to the pathogenesis of PAH. It has been 
suggested that both increased PASMC proliferation and decreased PASMC apoptosis 
have a relevant impact on pulmonary vasculature (Gurbanov and Shiliang 2006). 
Apoptosis, or programmed cell death, is an important biological process that has 
been connected to atherosclerosis, cancer, neurodegenerative disorders and pulmonary 
vascular diseases including PAH (Haunstetter and Izumo 1998; Lin et al. 2002). This 
cellular mechanism may significantly contribute to regression of pulmonary vascular 
remodeling by the loss of PASMC and reverse pulmonary pressure. One of the stimuli 
which activates apoptotic cell death is tumor necrosis factor (TNF)-α. Treatment of cells 
with extracellular TNF-α results in NF-κB-dependent gene expression leading, finally, to 
cell death (Gurbanov and Shiliang 2006). It has been demonstrated in human embronic 
kidney 293 cells that upon TNF-α stimulation, PRMT1, CARM1, p65, PARP1 and p300 
form a complex, which coactivates NF-κB-mediated transcription. Further experiments 
on modulation of PRMT1 expression have suggested that NF-Bκ-dependent gene 
activation might be positively regulated by PRMT1 expression (Hassa et al. 2008). These 
findings suggest a direct link between PRMT1 expression and regulation of PASMC 
growth. In sum, decreased PRMT1 levels might simultaneously result in increased cell 
proliferation and reduced apoptosis of PASMC.  
 
5.3 Conclusions and further perspectives  
Methylation of arginine residues plays a fundamental role in cellular processes, 
such as RNA maturation, DNA repair, signal transduction, protein-protein interaction, 
protein localization, translation and transcription. One product of this posttranslational 
modification, ADMA, has been implicated in the pathogenesis of several cardiovascular 
disorders, such as hypercholesterolemia, atherosclerosis, and PAH. To date, the interplay 
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between methylarginine synthesis and degradation in cardiovascular disorders has not 
been described.  
To conclude, findings reported in this study describe a novel method for the 
accurate quantification of arginine methylation in complex biological samples. In vivo 
studies on mice can be summarized as: 1) pulmonary expression of type I PRMTs was 
correlated with enhanced protein arginine methylation of the lung proteome;  
2) pulmonary ADMA degradation was undertaken by DDAH1; and 3) BAL fluid and 
serum exhibited almost identical ADMA/SDMA ratios. Together, these observations 
suggest that methylarginine metabolism by the lung significantly contributes to 
circulating ADMA and SDMA levels. 
Studies on PAH patients revealed significantly lower levels of protein-incorporated 
ADMA in the lungs of PAH patients compared with controls. Western blot analyses 
demonstrated significantly decreased expression of PRMT1 and asymmetrically 
dimethylated proteins in lungs from PAH patients. Immunohistochemistry localized 
PRMT1 expression to PASMC, where it was expressed in the nucleus and the cytosol. 
The knockdown of PRMT1 in primary PASMC by siRNA technology decreased the level 
of asymmetrically dimethylated proteins, and led to increased PASMC proliferation. 
These findings indicated the direct involvement of PRMT1 in the pathogenesis of PAH, 
and the progression of pulmonary vascular remodeling controlled by PASMC. It would 
be of interest to elucidate whether methylation of Sam68 regulates cellular processes, 
which are connected to the development of pulmonary arterial hypertension, for instance 
smooth muscle cell proliferation. Moreover, PRMT1 might play an important role in the 
development of PAH by controling NF-κB-dependent gene expression, a well known 
mechanism of cell proliferation. Therefore, future studies will be focused on the 
involvement of PRMT1 in modulation of NF-κB signaling in PASMC. 
 
.  
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6 Appendix 
 
 
Gene BankTM 
Accession Number 
Forward primer 
(5′-3′) 
Reverse primer 
(5′-3′) 
Amplicon size 
(bp) 
Human PRMT1 
NM_198318.1 
GCTGAGGACATGAC
ATCCAA 
GAAGAGGTGCCGGT
TATGAA 
132 
Human PRMT4/CARM1 
NM_199141.1 
ACAGCGTCCTCATCC
AGTTC 
GCTGGGACAGGTAG
CCATAA 
162 
Human PBGD 
NM_000190.3 
CCCACGCGAATCACT
CTCAT 
TGTCTGGTAACGGCA
ATGCG 
69 
 
 
 
Primary Host 
Dilution 
Company  
Catalog 
number IB IHCH 
anti - CDK4 rabbit 1:1000  Santa Cruz 601 
DDAH1 goat 1:1000  Everest Biotech 05278 
DDAH2 goat 1:1000  Everest Biotech 05277 
anti - dimethyl-arginine 
(ASYM24) 
rabbit 1:500  Santa Cruz 07-414 
anti - lamin A/C mouse 1:2000  Santa Cruz 20681 
anti - PRMT1 rabbit 1:2000 1:250 Abcam 7027-200 
anti - PRMT2 rabbit 1:1000  Abcam 3763-100 
anti - PRMT3 rabbit 1:2000  Upstate 07-256 
anti - PRMT4 rabbit 1:1000  Upstate 07-080 
anti - PRMT5 rabbit 1:2000  Upstate 07-405 
anti - PRMT6 rabbit 1:500  Imgenex 12192 
anti - PRMT7 rabbit 1:500  Upstate 07-639 
anti - α−SMA mouse  1:500 Sigma-Aldrich A5228 
anti - β−SMA rabbit 1:2000  Cell signaling 4970 
anti - tubulin mouse 1:2000  Santa Cruz 5286 
 
Table 6.1 List of primers used for Quantitative RT-PCR amplification. 
Table 6.2 List of primary antiobodies used for immunoblotting (IB) and 
immunohistochemistry (IHCH). 
Appendix  78 
 
 
 
Secondary Host Dilution Company 
Catalog 
number 
HRP-conjugated  
anti-mouse IgG 
rabbit 1:3000 Pierce 31450 
HRP-conjugated  
anti-rabbit IgG 
goat 1:3000 Pierce 31460 
HRP-conjugated  
anti-goat IgG 
rabbit 1:3000 Pierce 31402 
 
 
 
siRNA Company 
Catalog 
number 
PRMT1 (human) Santa Cruz 41069 
Negative control siRNA#1 Ambion 4611 
 
 
 
Table 6.3 List of secondary antiobodies used for immunoblotting (IB). 
 
Table 6.4 List of siRNA sequences. 
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